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 Abstract i 
ABSTRACT 
There is an increasing demand for individualized, genotype-based health advice. The general 
population-based dietary recommendations do not always motivate people to change their life-
style, and partly following this, cardiovascular diseases (CVD) are a major cause of death in 
worldwide. Using genotype-based nutrition and health information (e.g. nutrigenetics) in health 
education is a relatively new approach, although genetic variation is known to cause individual 
differences in response to dietary factors. Response to changes in dietary fat quality varies, for 
example, among different APOE genotypes. Research in this field is challenging, because several 
non-modifiable (genetic, age, sex) and modifiable (e.g. lifestyle, dietary, physical activity) factors 
together and with interaction affect the risk of life-style related diseases (e.g. CVD). The other 
challenge is the psychological factors (e.g. anxiety, threat, stress, motivation, attitude), which also 
have an effect on health behavior. The genotype-based information is always a very sensitive 
topic, because it can also cause some negative consequences and feelings (e.g. depression, in-
creased anxiety). 
The aim of this series of studies was firstly to study how individual, genotype-based health 
information affects an individual’s health form three aspects, and secondly whether this could be 
one method in the future to prevent lifestyle-related diseases, such as CVD. The first study con-
centrated on the psychological effects; the focus of the second study was on health behavior ef-
fects, and the third study concentrated on clinical effects.  In the fourth study of this series, the 
focus was on all these three aspects and their associations with each other. The genetic risk and 
health information was the APOE gene and its effects on CVD.  
To study the effect of APOE genotype-based health information in prevention of CVD, a 
total of 151 volunteers attended the baseline assessments (T0), of which 122 healthy adults (aged 
20 – 67 y) passed the inclusion criteria and started the one-year intervention. The participants (n 
= 122) were randomized into a control group (n = 61) and an intervention group (n = 61). There 
were 21 participants in the intervention Ɛ4+ group (including APOE genotypes 3/4 and 4/4) and 
40 participants in the intervention Ɛ4- group (including APOE genotypes 2/3 and 3/3). The control 
group included 61 participants (including APOE genotypes 3/4, 4/4, 2/3, 3/3 and 2/2). The base-
line (T0) and follow-up assessments (T1, T2, T3) included detailed measurements of psycholog-
ical (threat and anxiety experience, stage of change), and behavioral (dietary fat quality, con-
sumption of vegetables, - high fat/sugar foods and –alcohol, physical activity and health and taste 
attitudes) and clinical factors (total-, LDL- HDL cholesterol, triglycerides, blood pressure, blood 
glucose (0h and 2h), body mass index, waist circumference and body fat percentage). During the 
intervention six different communication sessions (lectures on healthy lifestyle and nutri-
genomics, health messages by mail, and personal discussion with the doctor) were arranged. The 
intervention groups (Ɛ4+ and Ɛ4-) received their APOE genotype information and health message 
at the beginning of the intervention. The control group received their APOE genotype information 
after the intervention. For the analyses in this dissertation, the results for 106/107 participants 
were analyzed. In the intervention, there were 16 participants in the high-risk (Ɛ4+) group and 35 
in the low-risk (Ɛ4-) group. The control group had 55 participants in studies III-IV and 56 partic-
ipants in studies I-II. 
ii Abstract 
The intervention had both short-term (≤ 6 months) and long-term (12 months) effects on 
health behavior and clinical factors. The short-term effects were found in dietary fat quality and 
waist circumference. Dietary fat quality improved more in the Ɛ4+ group than the Ɛ4- and the 
control groups as the personal, genotype-based health information and waist circumference low-
ered more in the Ɛ4+ group compared with the control group. Both these changes differed signif-
icantly between the Ɛ4+ and control groups (p<0.05). A long-term effect was found in triglyceride 
values (p<0.05), which lowered more in Ɛ4+ compared with the control group during the inter-
vention. Short-term effects were also found in the threat experience, which increased mostly in 
the Ɛ4+ group after the genetic feedback (p<0.05), but it decreased after 12 months, although 
remaining at a higher level compared to the baseline (T0). In addition, Study IV found that 
changes in the psychological factors (anxiety and threat experience, motivation), health and taste 
attitudes, and health behaviors (dietary, alcohol consumption, and physical activity) did not di-
rectly explain the changes in triglyceride values and waist circumference. However, change 
caused by a threat experience may have affected the change in triglycerides through total- and 
HDL cholesterol.  
In conclusion, this dissertation study has given some indications that individual, genotype-
based health information could be one potential option in the future to prevent lifestyle-related 
diseases in public health care. The results of this study imply that personal genetic information, 
based on APOE, may have positive effects on dietary fat quality and some cardiovascular risk 
markers (e.g., improvement in triglyceride values and waist circumference). This study also sug-
gests that psychological factors (e.g. anxiety and threat experience) may not be an obstacle for 
healthy people to use genotype-based health information to promote healthy lifestyles. However, 
even in the case of very personal health information, in order to achieve a permanent health be-
havior change, it is important to include attitudes and other psychological factors (e.g. motiva-
tion), as well as intensive repetition and a longer intervention duration. This research will serve 
as a basis for future studies and its information can be used to develop targeted interventions, 
including health information based on genotyping that would aim at preventing lifestyle diseases. 
People’s interest in personalized health advices has increased, while also the costs of genetic 
screening have decreased. Therefore, generally speaking, it can be assumed that genetic screening 
as a part of the prevention of lifestyle-related diseases may become more common in the future. 
In consequence, more research is required about how to make genetic screening a practical tool 
in public health care, and how to efficiently achieve long-term changes. 
 
Keywords: APOE, attitudes, behavioral, cardiovascular risk markers, changes, clinical, dietary 
advice, dietary fat quality, genetic information, health behavior, health information, healthy life-
style, intervention, nutrigenetics, predictors, psychological factors, threat experience, triglycer-
ides, waist circumference 
 
 Suomenkielinen tiivistelmä iii 
SUOMENKIELINEN TIIVISTELMÄ 
Yksilöllisen, geenitietoon pohjautuvan terveysviestinnän tarve on lisääntynyt. Yleiset terveys-
suositukset eivät aina motivoi elämäntapamuutoksiin ja osittain tämän seurauksena sydän- ja ve-
risuonitaudit ovat suurin kuolinsyy maailmassa. Genotyyppiin pohjautuvan ravitsemus- ja terveys 
viestinnän (nutrigenetiikka) käyttö terveyskasvatuksessa on vielä suhteellisen uusi lähestymis-
tapa, vaikkakin tiedossa on, että geneettinen vaihtelu aiheuttaa yksilöllisiä eroja vasteessa eri 
ruoka-aineisiin. Esimerkiksi, vaste rasvan laadun muutoksiin vaihtelee APOE genotyyppien vä-
lillä.  Tutkimus tällä alalla on haastavaa, johtuen useista ei-muunneltavista (perimä, ikä, suku-
puoli) ja muunneltavista (esim. elämätavat, ruokavalio, fyysinen aktiivisuus) tekijöistä, jotka yh-
dessä ja vuorovaikutuksessa toistensa kanssa vaikuttavat elämäntapasairausten (esim. sydän- ja 
verisuonitaudit) riskiin. Toinen haaste on psykologiset tekijät (esim. ahdistus, uhka, stressi, mo-
tivaatio, asenteet), joilla on myös vaikutusta terveyskäyttäytymiseen. Geenitietoon pohjautuva 
viestintä on aina hyvin herkkä aihe, koska sillä voi olla myös negatiivisia seurauksia (esim. dep-
ressiota, lisääntynyttä ahdistusta). 
Väitöskirjatyössä selvitettiin, miten yksilöllinen, geenitietoon pohjautuva terveysviestintä 
vaikuttaa ihmisten terveyteen kolmella eri osa-alueella ja voiko geenitietoon pohjautuva terveys-
viestintä olla yksi mahdollinen menetelmä tulevaisuudessa elämäntapasairausten, kuten sydän- ja 
verisuonitautien ehkäisyssä. Geenitieto ja terveysviestintä pohjautuivat APOE geeniin ja sen vai-
kutuksiin sydän- ja verisuonitautien puhkeamisessa. Vaikutuksia selvitettiin psykologisissa (1. 
artikkeli), käyttäytymiseen liittyvissä (2. artikkeli) sekä kliinisissä tekijöissä (3. artikkeli). Nel-
jännessä osatutkimuksessa selvitettiin näiden kolmen eri osa-alueen vuorovaikutusta. 
Yhteensä 151 vapaaehtoista osallistui ensimmäisiin lähtötaso-mittauksiin. Heistä 122, ter-
vettä, iältään 20–67 -vuotiasta henkilöä hyväksyttiin vuoden kestävään interventio-tutkimukseen. 
Heidät satunnaistettiin kontrolli- (n = 61) ja interventioryhmään (n = 61), joista 21 osallistujaa oli 
intervention Ɛ4+ ryhmässä (APOE genotyypit 3/4 ja 4/4) ja 40 osallistujaa intervention Ɛ4- ryh-
mässä (APOE genotyypit 2/3 ja 3/3). Kontrolliryhmään kuului 61 osallistujaa (APOE genotyypit 
3/4, 4/4, 2/3, 3/3 ja 2/2). Lähtö- (T0) ja seurantamittauksissa (T1, T2, T3) oli kyselyjä psykologi-
sista vaikutuksista (uhkan- ja ahdistuksen kokeminen, muutosvaihe), terveyskäyttäytymisestä 
(rasvan laatu, kasvisten käyttö, runsas rasvaisten ja sokeristen ruokien käyttö, alkoholin kulutus 
ja liikunta-aktiivisuus) sekä terveys- ja makuasenteista. Mukana oli myös kliinisiä mittauksia 
(kokonais-, LDL-, HDL kolesteroli, triglyseridit, verenpaine, verensokeri (0h ja 2h), painoin-
deksi, rasvaprosentti ja vyötärönympärys). Intervention aikana järjestettiin kuusi erilaista viestin-
tätilaisuutta (luentoja terveellisestä elämäntavasta ja nutrigenomiikasta, viestejä sähköpostitse 
sekä henkilökohtainen keskustelu lääkärin kanssa). Interventioryhmä sai tietää oman APOE gee-
nitietonsa intervention alussa, mutta kontrolliryhmä sai tietää sen vasta intervention päätyttyä. 
Yhteensä 106/107 henkilön tulokset analysoitiin tässä väitöskirjassa. Intervention korkean riskin 
(Ɛ4+) ryhmässä oli 16 henkilöä ja matalan riskin (Ɛ4-) ryhmässä 35 henkilöä. Kontrolliryhmässä 
oli 55 henkilöä osatutkimuksissa III-IV ja 56 henkilöä osatutkimuksissa I-II. 
Interventiolla oli sekä lyhyt- (≤6 kk) että pitkäaikaisia (12 kk) vaikutuksia terveyskäyttäy-
tymiseen sekä kliinisiin riskitekijöihin. Lyhytaikaisia vaikutuksia huomattiin ruokavalion rasvan 
laadussa ja vyötärönympäryksessä. Rasvan laatu parani tilastollisesti merkitsevästi enemmän 
iv Suomenkielinen tiivistelmä 
(p<0.05) Ɛ4+ kuin Ɛ4- ja kontrolliryhmissä ja vyötärönympärys pieneni enemmän Ɛ4+ ryhmässä 
verrattuna kontrolliryhmään. Pitkäaikaisvaikutus huomattiin triglysedi-arvoissa, jotka alenivat 
enemmän Ɛ4+ ryhmässä verrattuna kontrolliryhmään. Lyhytaikaisvaikutuksia havaittiin myös 
uhkan kokemisessa, joka lisääntyi eniten Ɛ4+ ryhmässä geenitiedon saannin jälkeen (p<0.05), 
mutta väheni 12 kuukauden jälkeen, jääden kuitenkin hieman korkeammalle tasolle verrattuna 
lähtötasoon (T0). Lisäksi, osatutkimus IV havaitsi, että muutokset terveys- ja makuasenteissa, 
psykologisissa sekä käyttäytymistekijöissä eivät suoraan selittäneet muutoksia triglyserideissä ja 
vyötärönympäryksessä. Muutos uhkan kokemisessa saattoi kuitenkin vaikuttaa muutokseen 
triglyserideissä kokonais- ja HDL kolesterolin kautta. 
Väitöskirjatyön tulokset antoivat viitteitä siitä, että yksilöllinen, geenitietoon pohjautuva 
terveysviestintä voisi olla yksi mahdollinen vaihtoehto tulevaisuudessa ehkäistä elämäntapasai-
rausten puhkeamista myös julkisella sektorilla. Tulokset viittaavat siihen, että henkilökohtaisella 
APOE geenitietoon pohjautuvalla terveysviestinnällä on positiivisia vaikutuksia ruokavalion ras-
vanlaatuun sekä sydän- ja verisuonitautien riskitekijöihin, kuten triglyserideihin ja vyötärönym-
pärykseen. Väitöskirjatyö osoitti myös, että psykologiset tekijät (ahdistus ja uhkan kokeminen) 
eivät todennäköisesti ole este geenitietoon pohjautuvan terveysviestinnän käyttämiselle terveillä 
aikuisilla. Saavuttaakseen kuitenkin pysyvän terveyskäyttäytymismuutoksen, on asenteiden sekä 
muiden psykologisten tekijöiden (esim. motivaatio) vaikutus otettava huomioon. Myös intensii-
vinen toisto sekä pidempi intervention kesto ovat tärkeitä seikkoja suunniteltaessa jatkotutki-
musta. Tämä väitöskirjatyö tarjoaa perustan jatkotutkimukselle ja sen antia voidaan käyttää hy-
väksi suunniteltaessa räätälöityjä, geenitietoon pohjautuvaan terveysviestintään perustuvia inter-
ventioita elämäntapasairausten ehkäisemiseksi. Ihmisten kiinnostus yksilölliseen terveysneuvon-
taan on lisääntynyt, samalla kun myös geenitestauksen kustannukset ovat laskeneet. Joten ylei-
sesti ottaen, voitaneen ehkä todeta, että geenitestaus osana elämäntapasairausten ehkäisyä tulee 
yleistymään tulevaisuudessa ja siksi lisää tutkimusta tarvitaan siitä, miten saada geenitestauksesta 
ja geenitiedon käytöstä toimiva työkalu julkisessa terveydenhuollossa ja miten saada pitkäaikaisia 
muutoksia aikaan. 
 
Avainsanat: APOE, asenteet, geenitieto, interventio, kliininen, käyttäytymiseen liittyvät tekijät, 
muutos, nutrigenetiikka, psykologiset tekijät, ravitsemusneuvonta, ruokavalion rasvan laatu, sy-
dän- ja verisuonitautien riskitekijät, terveelliset elämäntavat, terveyskäyttäytyminen, terveysvies-
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 Introduction 1 
1 INTRODUCTION 
General health recommendations (e.g. eating 500 g vegetables per day, consuming not more 
than 10E% saturated fat per day and undertaking  endurance exercise at least twice a week) 
do not always motivate healthy people to change their lifestyle (Smith et al. 2004; Lovegrove 
and Gitau 2008; Minich and Bland 2013). Although these common health recommendations 
have been promoted globally for many years, lifestyle-related diseases (e.g. cardiovascular 
diseases (CVD)), are still the main cause of mortality and morbity in Finland, as well as 
worldwide (Vartiainen et al. 2010; Ordovás and Smith 2010; Borodulin et al. 2014) One rea-
son can be the individual differences in responding to dietary changes because of nutrient-
gene interactions (Kohlmeir 2013). A new approach and tool could be genotype-based nutri-
tion and health information (e.g., nutrigenetics) that aims to affect health behavior and lower 
the risk of lifestyle-related diseases (e.g., obesity, diabetes, cardiovascular diseases) (Ong and 
Pérusse 2011). Currently, several commercial companies already offer genetic testing to the 
public (Bloss et al. 2011; Voils et al. 2012). However, genetic screening in the prevention of 
lifestyle-related diseases is not routine practice in public health care, which can be due  the 
lack of know-how among health care professionals, the lack of resources, and the expense of 
the tests (Mountcastle-Shah and Holtzman 2000; Taloustutkimus Oy and The Finnish 
Innovation Fund 2013). In addition, a lack of clear guidelines and uniform policy is an obsta-
cle to using genetic screening in public health care in Finland (Taloustutkimus Oy and The 
Finnish Innovation Fund 2013).    
The number of studies focusing on using genetic information to promote lifestyle 
changes is limited (McBride et al. 2010) and the results have been contradictory (Harvey-
Berino et al. 2001; Marteau et al. 2004; Frosch et al. 2005; Chao et al. 2008; Bloss et al. 2011; 
Markowitz et al. 2011). Marteau et al. (2010) found, in their review that genetic information 
did not generally motivate people to stop smoking or increase exercising, but it may have 
some favorable effects on diet and lifestyle (Marteau et al. 2010). The challenges to this re-
search field emphasizes the multifactorial nature of lifestyle-related diseases (e.g. cardiovas-
cular disease (CVD)), because they are influenced by many environmental, modifiable (e.g. 
unhealthy dietary habits, physical inactivity, smoking) and also genetic, non-modifiable fac-
tors (Raitakari et al. 1995; O’Neil et al. 1997; Ma et al. 2000; Lusis 2000; Schuit et al. 2002; 
Cho et al. 2009). Individuals are known to differ as regards gene-nutrition interactions, there-
fore another challenge is to target tailored health messages and develop targeted interventions 
and strategies that provided the best nutrition to the largest number of individuals (Kohlmeir 
2013). There are several genes, which are known to affect our response to dietary components, 
especially dietary fat intake and dietary fatty acid composition while affecting the risk of 
metabolic diseases (Phillips 2013; Wetterstrand 2014). However, probably the most studied 
2 Introduction 
dietary fat-gene interaction is related to the APOE gene. APOE has three major alleles: ε2, ε3, 
and ε4 and several studies have shown that carriers of APOE 4 allele have better response to 
dietary fat changes than other allele carriers, but at the same they have a higher blood choles-
terol content and an increased risk of cardiovascular diseases than the carriers of other alleles 
(Masson et al. 2003; Minihane et al. 2007). However, controversial results have also found 
no connection at all between the different APOE genotypes and dietary fat (Minihane et al. 
2000; Egert et al. 2010).  
In addition to the multifactorial nature and targeting challenges, some challenges of us-
ing genetic screening also produce possible harmful psychological effects like fatalism, anx-
iety, depression, threat, and stress (Heshka et al. 2008; Collins et al. 2011); all of these may 
have an effect on health behavior. Usually, these psychological effects occurs quite soon after 
the genetic feedback, even within a few days or weeks, but these effects have been shown to 
be short-term (Heshka et al. 2008; Collins et al. 2011). In addition, genetic information, alt-
hough individual, can also have a broader effect, affecting the whole family if the risk for the 
disease can be inherited (Marteau & Weinman 2006; Peterson 2005).  
In this series of studies, the possibility to promote healthy lifestyles by genotype-based, 
personalized health information was investigated. The health information was tailored made 
and based on a real threat (measured APOE genotype) and an experience threat (measured by 
risk behavior diagnostic scale (RBD)) (Witte 2001). An Extended Parallel Process Model 
(EPPM) was used to create health messages (Witte 2001). The focus of the intervention was 
the effects on the psychological factors (state-anxiety, threat experience, stage of change), 
health behavior (dietary fat quality, consumption of vegetables, berries, fruits; consumption 
of alcohol and fatty and sugary foods; physical activity; health and taste attitudes), and cardi-
ovascular risk markers (serum lipids, blood glucose, blood pressure, body mass index, waist 
circumference, fat percentage).The intervention included both an active communication pe-
riod (during the first 6 months) and a follow-up period (during the last 6 months), during 
which the participants received no health communication from the research group. Secondary 
analyses were completed to clarify associations between different lifestyle factors (psycho-
logical, behavioral, and clinical). To best of the author’s knowledge, no fully comparative 
studies using personalized health information based on the APOE genotype with an aim to 
promote a healthy lifestyle and lower CVD risk have been published to date. Concentrating 
on one health aspect at time: (1) psychological, (2) health behavioral and (3) clinical, was 
important to achieve the best possible benefit and understanding of this unique, very interdis-
ciplinary research topic. 
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2 REVIEW OF THE LITERATURE 
The review of literature is based on intervention research. The first chapter (2.1 Changing 
health behavior) describes the theory behind health behavior change and focuses more on the 
conceptual issues of this dissertation. The second and third chapter (2.2 Genetic testing for 
preventive purpose in lifestyle related diseases) (2.3 Nutrigenomics) focus more on the tools 
and methods to achieve health behavior change. The fourth chapter describes the actual risk 
factors (2.4 Cardiovascular diseases (CVD)), and the targets of health behavior change. The 
last chapter (2.5 Previous studies utilizing genetic testing to achieve nutrition- and clinical 
related changes) describes the previous studies and outcomes of using these tools to achieve 
health behavior change. 
2.1 Changing health behavior 
2.1.1 Definition of health behavior  
Health behavior is a broad concept including the actions of individuals, groups and organiza-
tions, as well as background factors and consequences and it can be defined as a typical, 
individual model of choices in health related issues. Health behavior reflects a person's health 
beliefs, which usually means our lifestyle choices (e.g. dietary, smoking, physical activity, 
alcohol consumption).The definition also covers social change, policy development and im-
plementation, improved coping skills, and an enhanced equality of life. (Glanz et al. 2008) 
Gochman (1997) has defined health behavior as “those personal attributes such as beliefs, 
expectations, motives, values, perceptions, and other cognitive elements, personality charac-
teristics, including affective and emotional states and traits, and overt behavior patterns, ac-
tions, and habits that relate to health maintenance, to health restoration, and to health im-
provement” (Gohman 1997).  According to Kasl and Cobb (1966a, 1966b) health behavior 
can also be divided to three categories: (1) preventive health behavior, (2) illness behavior 
and (3) sick-role behavior (Kasl and Cobb 1966a; Kasl and Cobb 1966b).  The preventive 
health behavior was the focus of this dissertation study. 
According to Salmela et al. (2010) health behavior change requires an individual to de-
sire to change her/his behavior as well as environmental support for the change. There should 
not be obstacles in the environment to making a change, and the individual has to have the 
possibility and resources to change his/her health behavior (Salmela et al. 2010). In addition, 
the values and benefits of the change affect whether the individual is capable of making a 
change (Witte 2001).  
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2.1.2 Definition and characteristics of health communication 
Health communication is the study and use of different methods to advice and affect the de-
cisions of individuals and society to improve health by making health behavior changes 
(Freimuth and Quinn 2004). Health communication can be based on facts, emotions or expe-
riences and it can be either factual or fictional (Torkkola 2002). The focus of health commu-
nication is usually placed on changing existing health behavior (Fitzgibbon et al. 2007) and 
proposing actions described in the health message. There are several strategies in the planning 
and implementation of health communication, depending on the aims of the communication 
(Hornik and Kelly 2007). The utilization of emotions in health communication has been a 
popular strategy over the past decades (Witte and Allen 2000; Fishbein and Cappella 2006) 
and it was also utilized in this present study. The health communication can be based on 
intimidation, if the health threats are individually modifiable (Ruiter et al. 2003). An emotion 
based health communication is more persuasive than one without emotions (Keller et al. 2002; 
Keller et al. 2003).  
The planning and phrasing of the health message is important in order to produce the 
emotions necessary to motivate the health behavior changes. Chronology, persuasion, co-
gency, and appearance are critical points in the health message. The proposed change has to 
be described clearly and minutely in the message. In the emotion based health communication 
it is quite common to use a clearly described action instead of general recommendations (e.g. 
walk for 20 minutes a day NOT do more exercise) (Fitzgibbon et al. 2007). 
2.1.3 Health behavior change theories 
There is a wide spectrum of health behavior theories, which aim to explain the reasons for 
people’s health behavior and how to influence  health behavior (Glanz et al. 2008; Salmela et 
al. 2010). These theories can explain one or several factors in health behavior (e.g. motivation, 
attitude, intention) (Noar et al. 2007). However, nowadays there is no single correct theory or 
framework that governs the research and practice (Glanz et al. 2008). Instead of one single 
theory, it is possible to choose elements from several different theories for research work in 
order to further increase the understanding of health-related behaviors (Glanz et al. 2008).  
Despite this current trend of combining theories, there are some health behavior theories 
or models which are the most popular (e.g. Health Belief Model, Social Learning Theory, 
Social Cognitive Theory, Theory of Reasoned Action, Theory of Planned Behavior and  The 
Transtheoretical Model/ Stages of Change) (Glanz et al. 2008). These theories are cogni-
tional-, behavioral or motivational based (Glanz et al. 2008). In addition, the other health 
behavior trend can be found in the so called Fear Appeal Theories (Witte 2001). The first fear 
appeal theory was Fear-as-Acquired Drive Model, which originated in the 1950s (Witte 
2001). The other purely fear appeal theories were the Parallel Process Model, created by 
Leventhal (1970) and the Protection Motivation Theory, created by Rogers (1975) (Witte 
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2001). These theories suggest that a moderate amount of fear lead to the greatest health be-
havior change and they are based on creating risk message (Witte 2001). 
In this dissertation, the Extended Parallel Process Model (EPPM) was used, which is 
based on one of the most widely used theories, the Health Belief Model and one of the fear-
appeal theories the Protection Motivation Theory. The Health Belief Model contains several 
similar concepts (susceptibility, seriousness, benefits and barriers to a behavior, cues to ac-
tion, and self-efficacy) to the EPPM, which predict peoples’ actions in preventing, screening 
for, or controlling sickness conditions (Rosenstock 1974; Janz and Becker 1984).  According 
to the Protection Motivation Theory, the motivation or intention to implement behavior 
change  depends on two different, individual processes: (1) threat assessment and (2) evalua-
tion of survival (Rogers et al. 1983). It is the first theory that also includes health communi-
cating (Rogers et al. 1983). 
The limitation of the Health Belief Model is that it is a purely cognitively based model 
and does not consider the emotional component of behavior (Glanz et al. 2008). The model 
does not take account fear and threat, which have been noticed to significantly predict per-
ceived risk, benefits, self-efficacy, and actual behavior (Glanz et al. 2008). According to Witte 
(1992) fear is an essential part of health-related behavior, and he defines it as a negative emo-
tion accompanied by a high state of arousal (Witte 1992). On the other hand, the traditional 
Fear-Appeal Models do not place much credence on people’s self-efficacy, motivation and 
the way in which people initially process risk messages (Witte 2001). In contrast to the con-
ventional Fear-Appeal Models, EPPM suggests that two appraisals act consequently (Witte 
2001). First, the threat appraisal must generate a particular perceived threat before people 
even consider the recommended response in the efficacy appraisal (Witte 2001). In addition, 
EPPM makes distinction between threat and fear, as well as the danger control process and 
the fear control process (Witte 2001). 
Extended Parallel Process Model (EPPM) (Fig. 1) 
EPPM was created at the beginning of the 1990s, and it is a combination of the previous 
theoretical perspectives, mainly based on the Health Belief Model and Protection Motivation 
Theory (Witte 2001). The Bandura’s self-efficacy concept is also used in EPPM (Bandura 
1977) (Witte 2001). EPPM combines elements from fear appeal and behavioral change theo-
ries to explain the different responses to health threats (Witte 2001). 
According to the Extended Parallel Process Model (EPPM), people’s reaction towards 
a health communication depends on four things: How threatening and seriously people per-
ceived the disease, how susceptible they are to the disease, how great their self-efficacy is to 
implement the proposed method (for example: I am able to exercise regularly in order to 
prevent cardiovascular disease), and how efficient people consider the proposed method (for 
example: Doing exercise regularly prevents cardiovascular disease) (Witte 2001). According 
6 Review of the Literature 
to EPPM a health message works when it brings about a suitable amount of fear, but at same 
time allows the individual to feel that he/she has enough self-efficacy to observe the proposed 
action (Witte 2001). As long as self-efficacy and response efficacy are more powerful feelings 
than fear and susceptibility then the health message is working correctly. In this ideal situa-
tion, people work with the danger instead of the fear and they are able to act to prevent the 
threat (e.g. cardiovascular disease threat). (Witte 1992) 
There are a few studies which have utilized the EPPM model and  usually, the threat has 
been some disease (e.g. cancer, AIDS, CVD, Asthma or Influenza) (Witte 1991; Witte et al. 
1998; McKay et al. 2004; Goei et al. 2010; Prati et al. 2012; Krieger and Sarge 2013). Further, 
Wong & Cappella used smoking as a threat (Wong and Cappella 2009). To the best of the 
author’s knowledge, the study of McKay et al. (2004) is reportedly the only study so far (in 
addition this dissertation) to use EPPM in the context of CVD risk. Their recommended re-
sponse was to increase the consumption of B-vitamin-rich foods and multivitamins. The 
health threat was CVD. Their outcomes were promising, although they had several limitations 
in their data. (McKay et al. 2004). For example, those participants who received a high effi-
cacy message, had a higher food response and vitamin response efficacy and in addition, they 
had higher scores for their vitamin attitude compared to the group who received a low efficacy 
message (McKay et al. 2004).  
 
Figure 1. The Extended Parallel Process Model (EPPM) (according to Witte et al. 2001). 
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Health and taste attitudes  
The basic assumption behind the concept of attitudes and health behavior is that attitudes in 
some way guide, influence, direct, shape, and predict health behavior (Kraus 1995). However, 
despite several previous studies over the last decade propounding different aspects of the at-
titude-behavior-link, it is still questionable, how much these attitudes and beliefs about diet 
and lifestyle affect our responses to dietary recommendations (Glasman and Albarracín 2006; 
Hearty et al. 2007; Smith et al. 2008). There are few basic facts which have an effect on how 
the attitude-behavior-link works. First of all, attitudes, which people hold with the confidence, 
predict behavior better than ambivalent or inconsistent ones (Glasman and Albarracín 2006; 
Hearty et al. 2007). In addition, easily recollected attitudes (accessibility) predict behavior 
better than attitudes that are difficult to recall and attitudes based on direct experience promote 
greater attitude-behavior consistency than those based on indirect experience (Kraus 1995). 
According to Kraus et al. (1995) and Cooke & Sheeran’s (2004) accessibility and stability are 
the most important aspects of attitudes as regards affecting health behavior (Kraus 1995; 
Cooke and Sheeran 2004). The stability of information associated with attitudes may increase 
attitude-behavior correspondence (Doll and Ajzen 1992). 
Moreover, health and taste attitudes have been shown to have an effect on health behav-
ior (Hearty et al. 2007; Roininen et al. 2001; Zandstra et al. 2001) as permanent lifestyle 
change demands continuous work and usually requires several changes at the same time. 
Health-related attitudes especially have proved to be good predictors of healthy food choices 
in the diet (Zandstra et al. 2001; Roininen et al. 2001; Hearty et al. 2007). However, some 
studies have found no connection between health related attitudes and health behavior (Lloyd 
et al. 1993; Barker et al. 1995). Lloyd et al. (1993) observed that participants with a high-fat 
diet had similar attitudes to dietary changes compared with participants who had a low-fat 
diet ((Lloyd et al. 1993).  Some studies have found that by affecting parental eating attitudes 
it is possible to attain good and stable changes in children’s health behavior (Talvia et al. 
2011). Eating behavior and food choices are established early in life and they have a long-
term impact (Mikkilä et al. 2005). Talvia et al. (2010) found in their longitudinal, child-ori-
ented dietary intervention, that a parental high general health interest was associated with 
dietary indicators of healthy eating (e.g., low intake of saturated fat, high intake of fiber, and 
high consumption of vegetables and fruits). This also had an effect on the children’s dietary 
quality (Talvia et al. 2011). 
Furthermore, health-related attitudes vary between different countries, socioeconomic 
status, gender, and age (Kearney et al. 1998; Roininen et al. 2001; Hearty et al. 2007; Biltoft-
Jensen et al. 2009; Talvia et al. 2011). Some previous studies have shown that Americans 
were the most health- and the least pleasure-oriented and French the least health- and the most 
pleasure-oriented, while Belgian and Japanese participants were between these two groups 
(Glanz et al. 1997; Rozin et al. 1999). Glanz et al. (1997), for example, noticed that Americans 
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were more realistic in estimating their dietary fat than the Dutch (Glanz et al. 1997). In addi-
tion, literature has shown that women, older people, and those who are more highly educated 
usually have a more positive attitude toward health-related issues (Kearney et al. 1998; 
Roininen et al. 2001; Hearty et al. 2007; Biltoft-Jensen et al. 2009; Talvia et al. 2011), and 
that aging increases interest in health and nutrition, partly due to disease avoidance (Olsen 
2003).   
2.2 Genetic testing for preventive purpose in lifestyle related diseases 
Although health education and general health recommendations—related to healthy eating, 
exercise and non-smoking—have been promoted globally for many years, there is a consid-
erable challenge in tailoring this information to individuals (Kreuter et al. 1999). Lifestyle 
related diseases (e.g. CVD) are still a major cause of death in Finland and worldwide, and 
genetic factors in combination with the an individual’s own lifestyle choices (e.g. dietary 
habits, physical activity, smoking) affect the risk for CVD (Vartiainen et al. 2010; Ordovás 
and Smith 2010; Borodulin et al. 2014). Partly because of this there is a need for individual-
ized information and new tools to promote healthy lifestyle changes (Gramling et al. 2003; 
Smith et al. 2004). Genetic information, including susceptibility to illness, is one method to 
motivate people to change unhealthy lifestyles (Lovegrove and Gitau 2008). Genetic infor-
mation can act as a motivator if a person already has a risk factor for a disease (e.g., high 
cholesterol, overweight) and they want to change their health behavior in a relatively easy 
way (Fishbein and Cappella 2006; Stewart-Knox et al. 2009). Both the genetic susceptibility 
and the already existing risk factor (e.g. high cholesterol) can together increase the disease 
threat (e.g. CVD) and motivate further the need for lifestyle changes. However, the number 
of threat experiences should be moderate, and not induce fear (Witte 1992).  The use of ge-
netic profiling and providing risk information is intended to provoke people into being con-
cerned about their lifestyles.  
2.2.1 Definition and categories of genetic testing 
The official definition of genetic testing varies between countries, context, tested material, 
method, and purpose. There are often overlaps with the term “genetic testing”, “genetic in-
formation” and “genetic counseling” and there is no standard definition (Varga et al. 2012).	
However, according to the European Commission (2004) the genetic testing is the analyses 
performed on human DNA and RNA, genes and chromosomes to identify inheritable or ac-
quired genotypes, mutations, phenotypes, or karyotypes that can cause a specific disease or 
conditions (European Commission 2004).	Another general and more technical definition is 
for example in Hungary: “Genetic test is a laboratory test aimed at disclosing DNA and/or 
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chromosome variations and their specific protein products, which are accompanied by or pre-
dict effects that have an adverse influence of human health. Types of genetic test include 
diagnostic, presymptomatic, predictive, heterozygote and prenatal tests. Genetic screening is 
a wide-range programmed genetic test provided to a population or a group of population for 
the purpose of identifying certain genetic characteristics in asymptomatic persons” (Varga et 
al. 2012). 
The methods used for genetic screening also create some challenges to giving a precise 
definition. Molecular genetic tests (or gene tests) study single genes or short lengths of DNA 
to identify variations or mutations that lead to a genetic disorder (Kohlmeir 2013). Chromo-
somal genetic tests analyze whole chromosomes or long lengths of DNA to see if there are 
large genetic changes, such as an extra copy of a chromosome, that cause a genetic condition 
(Kohlmeir 2013). Biochemical genetic tests study the number or activity level of proteins; 
abnormalities in either can indicate changes to the DNA that result in a genetic disorder 
(Kohlmeir 2013).  
Genetic testing can be either diagnostic or predictive testing (Evans et al. 2001). A di-
agnostic test is similar to a conventional medical test, such as a basic blood count, as they 
both give information about a current condition (Aktan-Collan 2001). In contrast, predictive 
genetic testing provides information about the probability of contracting the disease, with 
uncertainty (Aktan-Collan 2001).  In lifestyle related diseases, (e.g. CVD) the result of genetic 
testing gives only the susceptibility to contract a disease. Several factors (e.g., biological, 
learned, sociocultural, material-economic) affect the onset of life-style related diseases.  
There are several options when performing the genetic testing. Traditionally (patholog-
ical) genetic testing includes diagnostic, screening, and predictive tests for a disease (e.g. 
looking for breast cancer or Alzheimer disease) (Nyrhinen 2007; Kohlmeir 2013). These are 
usually done in health care situations with a doctor and a genetic counselor. The new area is 
in nonpathological testing (e.g. nutrigenetic tests). It is possible to discover the interactions 
between diet and genotypes on health and disease by nutrigenetic testing. These tests are usu-
ally commercial or direct-to-consumer testing. The commercial tests are done for profit and 
it can be either pathological or nonpathological (Kohlmeir 2013). The difference in the direct-
to-consumer tests is that there is a physician or genetic counselor involved in the process. The 
direct-to-consumer tests do not offer a possibility of genetic counseling and an individual is 
alone with the genetic testing results. In addition, the nutritional advice given with the tests is 
very general without any emotional support. (Kohlmeir 2013) Predictive, nutrigenetic testing 
was used in this dissertation.  
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2.2.2 Definition of genetic information 
Genetic information has certain properties, which distinguishes it from other health infor-
mation. Human genetic data has a special status, because genetic information, although per-
sonal can reveal future health risks and also affect the whole family, particularly as the risk 
for a disease can be inherited (Peterson 2005; Marteau and Weinman 2006; Nyrhinen 2007; 
Kohlmeir 2013). Genetic information includes information about an individual’s and also 
their family members genetic tests, their medical history, the individual’s request  for, or re-
ceipt of genetic services, or participation clinical trials with the genetic testing (Kohlmeir 
2013). The term ‘genetic information’ does not have an established definition, but it covers 
the all information about an individual’s genome. The genome alone or in combination with 
the environmental factors can influence risk of the disease. The genetic information is the 
hereditary information about genes, gene products or other inherited characteristics contained 
in chromosomal DNA or RNA that are derived from individual, families or population s 
(Kohlmeir 2013). The raw genetic information is the particular genetic variants (e.g.  Taq1 t 
(rs731236) or/and gene sequence (e.g. CCCATAGGAACA…).  The derived genetic infor-
mation consists of the explanation and meaning of the raw genetic information (e.g. …you 
have susceptibility to higher cholesterol). The derived genetic information reports only on the 
information an individual is tested for, not any extra results, which may not have any meaning 
for the individual or they do not necessary want to hear (e.g. … susceptibility to Alzheimer 
disease). (Kohlmeir 2013) In this dissertation the term ‘genetic information’ was used to de-
fine derived genetic information.  
2.2.3 Genetic counseling 
The definition of genetic counseling has been described as follows: “The genetic counseling 
is the process of helping people to understand and adapt to the medical, psychological, and 
familial implications of genetic contributions to disease. There are three steps in this process: 
“(1) interpretation of family and medical histories to assess the chance of disease occurrence 
or recurrence, (2) education about inheritance, testing, management, prevention, resources 
and research, and (3) counseling to promote informed choices and adaptation to the risk or 
condition.” (Resta et al. 2006) 
This definition does not determine who is qualified to give genetic counseling. Nowa-
days, the trend is that healthy individuals, who want to learn about their genotype, for exam-
ple, in order to diminish anxiety, uncertainty, or make personal and medical decisions, need 
genetic counseling. This creates opportunities as well as challenges for many physicians and 
doctors in a growing, preventive genetic testing field; this is because there is a lack of know-
how among health care professionals and a lack of resources (Mountcastle-Shah and 
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Holtzman 2000; Taloustutkimus Oy and The Finnish Innovation Fund 2013). Genetic coun-
seling requires a team effort from a number of different fields, such as nutrition, dietetics, 
genetics, biochemistry, and molecular biology (Juma et al. 2014).  
2.2.4 Psychological and ethical aspects of genetic testing 
As genetic testing can either reveal a susceptibility to or a decreased risk for a disease, or be 
neutral, the psychological and ethical issues are also of concern when receiving results. Ge-
netic information, although personal, can also affect the whole family, particularly as the risk 
for a disease can be heritable (Marteau & Weinman 2006; Peterson 2005).  
In several previous studies, genetic information has been related to harmful psycholog-
ical effects like fatalism, anxiety, depression, threat, and stress (Heshka et al. 2008; Collins et 
al. 2011). These psychological effects can occur quite soon after the genetic-risk feedback is 
given, even within a few days or weeks, but these changes usually also disappear quickly 
(Heshka et al. 2008; Collins et al. 2011). The genetic risk information can cause stress and 
anxiety, but at the same time it may alert people to the potential impact of their lifestyle 
choices, give hope and strengthen will and commitment (Aatre and Day 2011). The genetic 
information can also cause a sense of relief for a non-carrier, so it may also have some unfa-
vorable consequences for the health-related behavior of those with a low risk. It can provide 
an explanation for their unhealthy lifestyle because there is no recognized genetic suscepti-
bility to the disease (Lerman et al. 1997; McBride et al. 2002; Ito et al. 2006; Marteau and 
Weinman 2006; Lovegrove and Gitau 2008).  
In addition, the timing of the dissemination of genetic information has been shown to 
affect psychological responses. In the context of intense emotion and threat experience, peo-
ple may  not understand the genetic information and the risk properly, particularly if the re-
sults are opposite of those they expected (Smith et al. 2004; Heshka et al. 2008; Sanderson et 
al. 2009). At the same time, threat can be felt to be too frightening or too minor, depending 
on the emotional context (Smith et al. 2004; Heshka et al. 2008; Sanderson et al. 2009).  
In the context of genetic testing, four ethical principles have often described: the princi-
ples of autonomy, privacy, equality, and beneficence (Nyrhinen 2007). These principles em-
phasize the importance of informed consent, which means that individuals have the right to 
be informed, or not to be informed, have the right to privacy and confidentiality, and the right 
to control their own information (Teicher-Zallen 2009; Gefenas et al. 2011; Kohlmeir 2013). 
There are only a few situations where the genetic testing is compulsory (e.g. paternity testing 
in newborn child) (Kohlmeir 2013), otherwise, individuals have the freedom to choose 
whether they receive the results of gene test (Kohlmeir 2013). Other important ethical issues 
are clinical efficacy of revealing susceptibility to a disease, for which there is no treatment 
(e.g. Alzheimer disease), misdiagnoses (false positives or false negatives), misinterpretation 
of genetic results, too much unnecessary information and misuse of genetic information (e.g. 
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education, employment, insurance) (Lovegrove and Gitau 2008; Gefenas et al. 2011; 
Kohlmeir 2013).  One concern is the lack of health literacy skills, because genetic information 
is not always fully understood and there are differences in how people interpret and under-
stand their results (Henneman et al. 2002; Marteau et al. 2004; Lillie et al. 2007; Claassen et 
al. 2010; McBride et al. 2010). The consultation and information are important, because they 
have a significant impact on the understanding of gene results and the experience of worry 
(Henneman et al. 2002).  
2.3 Nutrigenomics (Fig.2) 
Nutrigenomics is a recently launched multidisciplinary research field, which focuses on many 
aspects; complex gene-environment interactions, the effects of nutrients on these interactions, 
the mechanism behind these nutrient effects and genotypes, and how these interactions affect 
the balance between health and disease (DeBusk 2009). The use of genotype-based nutrition 
and health information that aim to affect health behavior and lower the risk of lifestyle-related 
diseases (e.g., obesity, diabetes, cardiovascular diseases) is a relatively new approach in 
health education (Smith et al. 2004; Lovegrove and Gitau 2008; Ong and Pérusse 2011). 
Nutrigenomics and nutrigenetics are defined as the science of the effect of genetic vari-
ation on dietary response and the role of nutrients and bioactive food compounds in gene 
expression (Ordovas and Corella 2004; Trujillo et al. 2006; Kaput 2008; Corella and Ordovas 
2009; Ferguson 2009; Simopoulos 2010). There is also a difference between the definitions 
of ‘Nutrigenetics’ and ‘Nutrigenomics’. Nutrigenetics is a science that explores the interac-
tions of our inherited genome and nutrition (dietary responses) and the use of this information 
in practice (Simopoulos 2010; Kohlmeir 2013). The term ‘nutrigenetics’ was used for the first 
time by Dry R. O Brennan in 1975 (Farhud et al. 2010). Nutrigenomics is a broader concept, 
which includes all genetic differences (nutrigenetics), and also gene regulation by nutrients, 
gene expression and epigenetics (effects of DNA and RNA modifications on gene properties 
and behavior) (Simopoulos 2010; Kohlmeir 2013).  
There is wide spectrum of genetic-dietary interactions. Genetic differences are known 
to affect almost every nutrient metabolism in some way (protein-, carbohydrates-, lipids-, 
sterols-, minerals-, vitamins-, trace elements-, alcohol metabolism) and disorders or deficien-
cies in a gene may cause health problems, which vary in severity. In phenylketonuria disease, 
for example, conversion of phenylalanine to amino acid L-tyrosine is defective, which leads 
to an accumulation of phenylalanine in blood (Kohlmeir 2013). Tyrosine is needed for the 
synthesis of proteins, compounds acting neurotransmitters, hormones (adrenaline, noradren-
aline and dopamine), and melanin (Kohlmeir 2013). Excessive amounts of phenylalanine me-
tabolites and a deficiency of tyrosine cause irreversible damage to the central nervous system 
(Kohlmeir 2013). However, fortunately all these deficiencies in genetic-dietary interactions 
are not so harmful. In lactose-intolerance disorder, for example, the gene (LCT gene), which 
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encodes the lactose-digesting enzyme (Lactase) is missing or is not working completely 
(Kohlmeir 2013). Several other genes’ polymorphs can also affect the property of lactose 
intolerance. A mutation in MCM6 gene, for example, enables people to tolerate lactose and 
dairy products and it is common in Europe (Kohlmeir 2013). The lactose-intolerance disorder 
causes abdominal cramps, bloating, or diarrhea, when drinking milk with lactose. The world-
wide prevalence of lactose-intolerance disorder is 60-70 % and it is very common in Finland 
(Kohlmeir 2013). 
 
Figure 2. Nutrigenomics (according to Kohlemeir 2013). 
2.3.1 Nutrigenomics in lipid and cholesterol metabolism  
In the past few decades nutrigenomics has concentrated on lipid and cholesterol metabolism, 
especially those genetic differences which predispose to obesity, higher cholesterol, and met-
abolic syndrome (MeS) (Kohlmeir 2013). The research in this field is relatively new com-
pared with carbohydrate- or protein metabolism and evidence, the effects of genetic variations 
on heterogeneity in lipid responses is still limited, but suggestive (Koriyama et al. 2012; 
Kohlmeir 2013). However, the research in this field is increasing and will continue to do so 
in the future. This is because chronic diseases (e.g. cardiovascular diseases) are a major cause 
of death worldwide and lipid and cholesterol metabolism have a central role in preventing 
these diseases (Lovegrove and Gitau 2008; Koriyama et al. 2012). Multiple genes, rather than 
one single gene, together with environmental factors and especially the mechanism of dietary 
components in lipid metabolism are currently popular research topic, and will also be in the 
future (Koriyama et al. 2012). 
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Although the evidence is limited, there is wide spectrum of genetic variants which have 
observed to affect the response to dietary fat and sterol intake and only a few that are the most 
known are presented in this dissertation study.  Genes, CD36 and FTO, for example, have 
been associated with obesity (Keller et al. 2012; Moleres et al. 2012). The response toward 
saturated fat differs between CD36 and FTO-gene variants. Lack of the FTO variant 
(rs9939609), for example, may protect from obesity, even if an individual eats considerable 
amounts of saturated fat (Moleres et al. 2012). In addition, the APOA2 gene has been found 
to have a role in protecting against the development of metabolic syndrome (Smith et al. 
2012). This protection effect varies between different variants and especially in carriers with 
the APOA2 – 265C/C genotype, low saturated fat intake has been associated with the lower 
BMI than other genotypes (Smith et al. 2012). 
Several genes also have functions in cholesterol metabolism (e.g. APOE, APOA1, 
APOA4, APOB, FADS, MTP, MTTP (-493T/T), ABCG5) (Koriyama et al. 2012; Kohlmeir 
2013). These genes have several variants, which may either have or not have an effect on 
LDL or HDL cholesterol and the data is still partly contradictory on this point (Koriyama et 
al. 2012; Kohlmeir 2013). The findings are mainly based on individual studies, for example 
high polyunsaturated fatty acid (PUFA) has been associated with the higher HDL cholesterol 
concentration among APOA1 – 75A carriers (Ordovas et al. 2002), and carriers with the 
FADS1 (rs174546, T-allele) tended to have about 5 % lower serum cholesterol concentration, 
if their dietary alpha-linoleic acid (ALA) was greater than 1.4 g/day (Dumont et al. 2011). In 
addition, the gene ABCG5 with the two C-alleles have been associated with higher blood 
cholesterol concentration compared with the carriers of G-alleles (Herron et al. 2006) and 
APOA4 360His variant carriers have a decreased cholesterol response to cholesterol intake 
(Ordovas et al. 1995). 
Nutrigenetics and APOE gene 
Overall, the most studied gene in dietary fat response and cholesterol metabolism is APOE 
gene (Minihane et al. 2007; Lovegrove and Gitau 2008), and it is the most convincing. The 
response of individuals to dietary fat varies (Masson et al. 2003; Minihane et al. 2007) and 
this heterogeneity is partly dependent on three major APOE alleles ԑ2, ԑ3 and ԑ4 (Lovegrove 
and Gitau 2008). The apolipoprotein (apoE) contains 299 amino acids and it has many func-
tions in cholesterol and lipoprotein metabolism (e.g. low-density (LDL)-, high-density 
(HDL)- and very low-density (VLDL) lipoprotein and chylomicron metabolism) (Koriyama 
et al. 2012). The apoE binds several lipoprotein receptors (Koriyama et al. 2012).  There is 
evidence that APOE 4 carriers usually have a higher blood cholesterol content and an in-
creased risk for cardiovascular diseases than the carriers of other alleles (Masson et al. 2003; 
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Ordovas and Corella 2004; Minihane et al. 2007), but on the other hand they are more respon-
sive to changes in dietary fat than other APOE carriers (Masson et al. 2003; Ordovas and 
Corella 2004; Carvalho-Wells et al. 2012).  
Several studies have found a difference in LDL cholesterol level between ԑ2 and ԑ4 
alleles, the level being higher among carriers of the ԑ4 allele (Kuusisto et al. 1995; Pablos-
Méndez et al. 1997; Bercedo-Sanz et al. 1999; Minihane et al. 2000; Corella et al. 2001; 
Beilby et al. 2003; Marques-Vidal et al. 2003; Rastas et al. 2004; Shin et al. 2005). Shin et al. 
(2005), for example found in their study of healthy people (age 45 – 74 y, n = 1232 (female)) 
that LDL cholesterol among APOE 2 carriers was 2.8 mmol/l, while it was 0.6 mmol/l higher 
among APOE 4 carriers (Shin et al. 2005).  Higher LDL cholesterol has also been found 
among carriers of APOE 4 allele compared to APOE 3 carriers (Srinivasan et al. 1999; 
Sheehan et al. 2000; Ranjith et al. 2004; Saito et al. 2004; Almeida et al. 2006), although the 
difference was minor between the APOE 4 carriers and 3 carriers compared with the differ-
ence in APOE 4 carriers and 2 carriers. Sheehan et al. (2000), for example found in their study 
of healthy people (aged 19 – 67 y) that LDL cholesterol level among the carriers of APOE 4 
allele was 2.86 mmol/l, while among carriers of APOE 3 allele it was 2.39 mmol/l and among 
carriers of APOE 2 allele 2.27 mmol/l (Sheehan et al. 2000). The age, gender, disease status, 
and drug use may also bring some variations in serum lipids levels and responses to changes 
in dietary fat among different APOE genotypes (Lovegrove and Gitau 2008). Carvalho-Wells 
et al. (2010) study found that age has a remarkable effect on lipid concentration on the differ-
ent APOE genotypes(Carvalho-Wells et al. 2010). Their study indicated that total- and LDL 
cholesterol, and triglyceride content were higher and HDL cholesterol was lower with indi-
viduals of APOE 2 allele compared to individuals with APOE 4 allele in a subgroup that were 
50 years or under, whereas in the subgroup over 50 years the results were the opposite 
(Carvalho-Wells et al. 2010).  
Masson et al. (2003) in their systematic review (46 studies) studied the connection be-
tween different APOE genotypes and responses to dietary fat. A significantly different num-
ber of  LDL, HDL-cholesterol or triglycerides responses were found in 19 studies, mostly in 
the LDL-cholesterol (12 studies) of which APOE4 individuals tended to be the most respon-
sive (8 studies) (Masson et al. 2003). In addition, the recent study by Carvalho-Wells et al. 
(2012) found a greater responsive in triglyceride content to dietary fat manipulation among 
APOE 3/4 genotypes compared with the APOE 3/3 genotypes (Carvalho-Wells et al. 2012). 
Although the review by Masson et al. (2003) showed that individuals with the APOE 4 
allele appear to be most responsive to changes in dietary fat, their study also concluded that 
carriers of the APOE 4 allele may not be the most responsive to changes in other aspect of 
diet (Masson et al. 2003). In addition, several controversial or no associations at all have been 
presented (Minihane et al. 2000; Masson et al. 2003; Olano-Martin et al. 2010; Egert et al. 
2010; Liang et al. 2013).  Liang et al. (2013), for example did not find a different response 
16 Review of the Literature 
toward fish oil fatty acids eicosapentaenoic (EPA) among APOE genotypes. The only signif-
icant response was seen in HDL-cholesterol among APOE 2 carriers (Liang et al. 2013). Fur-
ther, Minihane et al. (2000) showed in their studies that APOE ԑ4 carriers’ total cholesterol 
and LDL cholesterol increased after a fish oil supplementation, and HDL cholesterol de-
creased compared with APOE ԑ3 carriers (Minihane et al. 2000). In addition, Egert et al. 
(2010) found that APOE ԑ3 carriers had a better response to quercetin (flavonols) supplemen-
tation than APOE ԑ4 carriers (Egert et al. 2010). The differences were revealed in systolic 
blood pressure, HDL cholesterol, and the ratio of LDL:HDL cholesterol (Egert et al. 2010). 
Several previous studies have also demonstrated the connection of APOE 2 and 4 alleles to 
higher triglyceride content than APOE 3 allele (Dallongeville et al. 1992; Luc et al. 1994; 
Tiret et al. 1994; Haffner et al. 1996; Tammi et al. 2000; Haddy et al. 2002). Additionally, 
some studies with mice have also found connections between a high-fat and high-cholesterol 
diet and extensive atherosclerotic plaques caused by a high- fat and cholesterol diet and the 
APOE 2/2 genotypes (Sullivan et al. 1998; Mihovilovic et al. 2007). This connection was not 
found in APOE 3/3 genotypes. 
The APOE also have other nutritional related functions, including  vitamin E, D and K 
metabolism (Kohlmeier et al. 1998; Lovegrove and Gitau 2008; Huebbe et al. 2010; Huebbe 
et al. 2011; Vermeer 2012). Some previous studies have found that individuals with the APOE 
4 allele are better able to tolerate D vitamin deficiency compared with the carriers of other 
APOE alleles (Ulrik Gerdes 2003; Huebbe et al. 2011). This is the case mainly in circum-
stances in which vitamin D production or intake is decreased (e.g. high geographical latitude, 
dark skin, or insufficient dietary supplementation) (Ulrik Gerdes 2003; Huebbe et al. 2011). 
Higher D-vitamin concentrations among APOE 4 carriers may be due to a better absorption 
of dietary fats and renal retention (Huebbe et al. 2011). Further, the APOE 4 allele can be 
associated with lower vitamin E retention in peripheral tissue (Huebbe et al. 2010) and a lower 
level of vitamin K concentration in blood. Both, APOE 4 allele and deficiency of vitamin E 
has also been associated with an increased risk for Alzheimer disease (AD). Lower vitamin 
K concentration among APOE 4 carriers has been associated with an increased risk for oste-
oporosis and bone fractures (Kohlmeier et al. 1998). Increased alcohol consumption has also 
associated with an increased LDL-cholesterol level among APOE 4 carriers (Ordovas 2002). 
Prevalence of APOE genotypes (table 1) 
The most common APOE allele in all human populations is APOE 3, but there are great re-
gional differences in number of APOE 4 carriers (Lehtimäki et al. 1990; Corbo and Scacchi 
1999; Schiele et al. 2000). Humans with APOE 4 allele are more common in ethnic and abo-
riginal groups such as African Pygmies and the Khoi San, as well as aborigines of Malaysia 
and Australia (Corbo and Scacchi 1999). In Europe, there is a geographical limit between 
South and North in prevalence of the APOE 4 allele (Corbo and Scacchi 1999; Minihane et 
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al. 2000; Schiele et al. 2000; Singh et al. 2006) (table 1). Among northern Europeans, 30 % 
are APOE 4 carriers, whereas in South Europe correspondingly less than 20 % (Schiele et al. 
2000). Singh et al. (2006) observed the same phenomenon, although the prevalence of the 
APOE 4 allele was approximately 20 % in Northern Europe (e.g. Norway, Finland) (Singh et 
al. 2006) (table 1). Furthermore, previous studies observed that frequency of APOE 4 allele 
was higher among young Finns compared with most other populations (France, Germany, 
Scotland, USA, Canada, New Zealand, Singapore, Japan), but there were no regional differ-
ences in incidence of APOE genotypes. (Ehnholm et al. 1986; Lehtimäki et al. 1990; Corbo 
and Scacchi 1999; Schiele et al. 2000; Juonala et al. 2004).  
Table 1. Prevalence of APOE alleles in select countries worldwide (Singh 
et al. 2006; Minihane et al. 2007) 
 
2.3.2 Utilization of nutrigenetics by nutritional genetic testing 
Some researchers have predicted that nutritional genetic testing will become a routine and as 
commonplace as having a blood cholesterol test, thus changing the practice from generalized 
treatments to early detection and prevention based on a personal, genetic susceptibility 
(Lovegrove and Gitau 2008). The one assumption is that genetic testing will increase interest 
in healthy nutrition (Kohlmeir 2013). Utilizing nutrigenetic testing in genetic-nutrition related 
diseases, which can be controlled only by increasing, decreasing, or avoiding some food or 
food ingredient have been routine for several years (Ferguson 2014). Increasing folate, for 
example, is important for women whose metabolism works differently, to prevent neural tube 
defects in unborn children (Pogribna et al. 2001) and avoiding lactose in dairy products is 
important for people with an absence of the lactose-digesting enzyme lactase in the small 
Country n ԑ4 -% ԑ3 -% ԑ2 -%
Nigeria 781 25.2 68.4 6.4
Norway 798 19.8 74.4 5.8
Finland 1577 19.4 76.7 3.9
New Zealand 426 14.1 73.9 12.0
UK 621 13.7 72.2 14.2
Germany 1557 13.6 78.2 8.2
USA 1209 13.5 78.6 7.5
France 1228 12.1 77.1 10.8
Spain 614 7.8 84.2 8.0
India 4450 7.3 88.7 3.9
China 518 6.5 84.3 9.2
Italy 633 6.3 89.7 4.0
Turkey 8366 6.1 86.0 7.9
ApoE alleles
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intestine (Kohlmeir 2013). However, a new approach is to modify the standard nutrition ther-
apy by using nutritional genetic testing. This can be one tool that can be combined with indi-
vidual nutrition advice, such as increasing unsaturated fat intake to effect cholesterol level in 
prevention of life-style related diseases (e.g. CVD) (Ferguson 2014). However, using nutri-
genetic testing is only viable  if it brings actionable information based on convincing evidence 
(Kohlmeir 2013). The evidence has to come from a sufficient and comparable target popula-
tion, and the genetic analysis has to be reliable (Kohlmeir 2013). The challenge in utilizing 
nutritional genetic testing in lifestyle-related diseases is the multifactorial nature of these dis-
eases. The onset of the lifestyle-related disease (e.g. CVD) is affecting several genes, genetic-
nutrition interactions and lifestyle factors (e.g. dietary, smoking, alcohol consumption, phys-
ical activity). 
Partly due to these challenges, and also to the lack of know-how and resources among 
health care professionals the utilization of nutritional genetic testing in the prevention of life-
style related diseases is still in its infancy in public health care (Bloss et al. 2011; Rahman et 
al. 2012; Voils et al. 2012). This fact has offered an opportunity to several commercial com-
panies (DTC) to offer nutritional genetic testing to the public (Bloss et al. 2011; Rahman et 
al. 2012; Voils et al. 2012). Supplying the information for the genetic test is kept very simple 
in these DTC tests. The consumer is receives a simple sample collection kit from the testing 
company and usually takes a sample by noninvasive swabs from the inside of the cheek. After 
a few weeks, the tests results are returned as a printed or electronic report. A broad spectrum 
of these tests is available (e.g. for B vitamin metabolism, hearth health, alcohol metabolism, 
cholesterol metabolism, weight management) (Ferguson 2014) and the majority of these tests 
are based on one single nucleotide (SNP).  
There are also some ethical aspects to DTC nutritional genetic testing, which have been 
discussed previously in this dissertation (Chapters 2.2.1 and 2.2.4). The nutritional advice 
offered by DTC testing companies, is usually very generic and rarely meets the real need 
(Kohlmeir 2013). Consequently, the one challenge is to ensure an opportunity for appropriate 
genetic consultation for everyone. Nevertheless, DTC nutritional genetic testing can either 
decrease health care costs by increasing the prevalence of early detection and prevent the life-
style related disease or it can increase the costs by burdening the health care system with 
individuals who have ‘excessive anxiety and worry. Another special concern in DTC genetic 
testing is the lack of comprehensive service standards and validity of test interpretations 
(Kohlmeir 2013). In addition, an individuals’ personal genetic information may not suffi-
ciently protected, although the companies convince so (Kohlmeir 2013). 
2.4 Cardiovascular diseases (CVD) 
The cardiovascular diseases (CVD) consist of several disease conditions, which affect the 
heart and blood vessels (e.g. atherosclerotic heart disease, coronary heart disease (CHD), and 
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ischemic heart disease). Despite the major, favorable changes in cardiovascular diseases risk 
factors (CVD) over the past few decades, CVD are still the main cause of mortality and mor-
bidity in Finland as well as worldwide (Vartiainen et al. 2010; Ordovás and Smith 2010; 
Borodulin et al. 2014). The prevalence of CVD has increased clearly over the past 100 years 
(Ordovás and Smith 2010).  
2.4.1 Association of APOE genotype with cardiovascular diseases (CVD) 
The majority of studies have indicated an interaction between APOE genotypes and CVD, 
although there is discrepancy in the evidence of this causal relationship and other gene-nutri-
ent interactions (Lovegrove and Gitau 2008). This research field is very broad and there are 
several controversial results published (Gustavsson et al. 2012). However, there are some 
large studies, which support associations of APOE genotype with CVD (Song et al. 2004; 
Bennet et al. 2007; Holmes et al. 2014). The meta-analysis of Song et al. (2004), for example, 
showed that carriers of the APOE 4 allele may even have a 42-percent higher risk for CVD 
compared with the carriers of the APOE 3/3 genotype, although the evidence was based partly 
on studies which with less than 500 coronary cases (Song et al. 2004). However, the meta-
analysis of  Bennet et al. (2007) from over 86 000 healthy participants and from 37 850 cor-
onary cases (in total 203 studies) reported somewhat parallel results. The highest risk to Cor-
onary heart disease (CHD) was among the carriers of the APOE 4 allele, however, it was only 
6 % higher compared with the APOE 3/3 genotype. The lowest risk was among carriers of 
APOE 2 allele, being 26 % lower compared with the carriers of APOE 4 allele. (Bennet et al. 
2007) A very recent, systematic review and meta-analysis from over 130 000 individuals, also 
observed similar linear association (p = 0.046) between APOE genotypes and CHD risk 
(ԑ2/ԑ2, ԑ2/ԑ3, ԑ3/ԑ3, ԑ3/ԑ4, ԑ4/ԑ4); the risk being higher among carriers of APOE 4 allele and 
lower among carriers of APOE 2 allele (Holmes et al. 2014). 
As reported previously in this dissertation (Chapter 2.3.1 Nutrigenetics and APOE), the 
main role of APOE concerned with lipid metabolism and cholesterol absorption, which have 
major effects on cardiovascular disease risk. In addition, it has been suggested that APOE 
genotype also effects other cardiovascular risk factors (Rantala et al. 1997; Helkala et al. 
2001; Saito et al. 2004; Carvalho-Wells et al. 2010). High blood pressure has been associated 
with the presence of the APOE 4 allele (Rantala et al. 1997), but also with the APOE 2 allele 
(Couderc et al. 1993; Helkala et al. 2001; Cho et al. 2009). Furthermore, Helkala et al. (2001) 
found that carriers of the APOE 2 allele had a higher fasting glucose and 2 h blood glucose 
than APOE 3 and 4 carriers (Helkala et al. 2001). Previous and also some recent studies have 
also associated smoking  with the increased risk of CHD among APOE 4 carriers (Humphries 
et al. 2001; Gustavsson et al. 2012; Grammer et al. 2013). Gustavsson et al. (2012), for ex-
ample, found that smoking increases the CHD risk (P = 0.009) among female APOE 4 allele 
carriers, but not in male APOE 4 allele carriers and Grammer et al. (2013) reported higher 
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CVD risk and mortality (P = 0.034) among ‘current-smokers with APOE 4 allele’ compared 
with the ‘ex-smokers with APOE 4 allele’ or ‘not-smokers, with the APOE 4 allele’ 
(Gustavsson et al. 2012; Grammer et al. 2013). However, very recent review and meta-anal-
ysis did not find this connection (p = 0.19) between smoking, APOE genotypes, and CHD 
risk (Holmes et al. 2014). 
2.4.2 Risk factors for cardiovascular disease (Fig.3) 
The genetic factors in combination with the environment (e.g., unhealthy dietary habits, phys-
ical inactivity and smoking) play an important role in the prevalence of CVD (Lusis 2000; 
Cho et al. 2009). While gender, age, genetics, race and ethnicity are non-modifiable risk fac-
tors for CVD, modifiable key risk factors include obesity, smoking, high serum total choles-
terol and elevated systolic and diastolic blood pressure (Borodulin et al. 2014; Ferguson 2014; 
Juma et al. 2014).  Generally, men and older people have more CVD risk factors than women 
and younger people. Previous studies suggest that women’s advantage toward CVD risk fac-
tors compared with men is their insulin sensitivity (Nuutila et al. 1995; Willeit et al. 1997; 
Cnop et al. 2003; Moran et al. 2008; Ferrara et al. 2008; Ervin 2009; Kim and Reaven 2013).  
It has been shown that unhealthy lifestyle habits (e.g. physical inactivity, smoking, ex-
cessive consumption of alcohol and saturated fat and low consumption of vegetables) are 
closely linked to an increased risk of cardiovascular diseases (Raitakari et al. 1995; O’Neil et 
al. 1997; Ma et al. 2000; Schuit et al. 2002; Lukasiewicz et al. 2005). In addition, these risk 
factors tend to accumulate (Raitakari et al. 1995; O’Neil et al. 1997; Ma et al. 2000; Schuit et 
al. 2002; Artaud et al. 2013; Robinson et al. 2013).  
 
Figure 3. Modifiable and non-modifiable risk factors related to CVD. (derived from Juma et al. 2014)  
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Obesity 
Overweight in adults is categorized based on body mass index (BMI), which is calculated 
dividing weight (kg) by height (m) squared. BMI under 18.5 kg/m2 indicates underweight, 
BMI from 18.5 – 24.9 kg/m2  indicates normal weight and BMI 25.0 kg/m2 or higher indicates 
overweight (Tarnanen et al. 2011). However, classifying individuals as having ‘normal 
weight’ or being ‘obese’ only based on BMI is not correct. Overweight can be due to an 
increased amount of muscle tissue and BMI does not take a note the distribution of body fat. 
An accumulation of fat on the central part of the body is a more accurate and independent 
criterion for obesity and risk factors for metabolic disorders (Misra and Vikram 2003). Waist 
circumference reveals on amount of visceral fat and fat in the area of the abdominal cavity 
and it is one main criteria for metabolic syndrome (Mes) (Alberti et al. 2005).  Normal waist 
circumference for men is ≤94 cm and for women ≤80 cm. Over 102 cm for men and over 88 
cm for women indicates significant health risk.  
In addition, body fat percentage can have an impact on obesity. Women have higher 
body fat percentage compared with men due to hormonal reasons (Lemieux et al. 1994).  Nor-
mal body fat percentage for men is 8 - 21.9 % and for women 21 - 33.9 and it depends on age 
(Anonymous. Finnish electronic medical book. 2009). Smoking, excessive alcohol consump-
tion, and low intake of dietary fiber are known to increase central fat accumulation (Barrett-
Connor and Khaw 1989; Dallongeville et al. 1998; Ludwig et al. 1999; Koh-Banerjee et al. 
2003; Canoy et al. 2005; Lukasiewicz et al. 2005) 
Obesity is one of the main, well known,  modifiable risk factor to cardiovascular dis-
eases and it is usually a consequence of unhealthy dietary and physical inactivity, although 
several genes have also known to predispose to obesity (Hubert et al. 1983; Jonsson et al. 
2002; Sharma 2003; Haslam and James 2005; Kohlmeir 2013). The gene most often linked 
to fat mass and obesity is the FTO gene (Phillips et al. 2012). Some studies have also found 
genetic predisposition (variants in the UCP gene) to higher waist circumference (Martinez-
Hervas et al. 2012). 
Obesity has been shown to increase risk for hypertension and diabetes, which also in-
creases the risk for CVD (Sharma 2003; Lindström 2006). It has also shown that risk factors 
tend to accumulate (Raitakari et al. 1995; Schuit et al. 2002; Pronk et al. 2004; Lukasiewicz 
et al. 2005; Poortinga 2007; Artaud et al. 2013; Robinson et al. 2013). The longitudinal study 
(23 year follow-up, n = 22 025) of Jonsson et al. (2002) demonstrated that obesity was asso-
ciated to CVD mostly, if participants were also smokers (Jonsson et al. 2002).      
Obesity prevalence has increased throughout the world, although at the same time un-
derweight and malnutrition have also increased in developed countries (Silventoinen et al. 
2004). In Finland, overweight is still a major concern (Helakorpi et al. 2008; Vartiainen et al. 
2010; Helakorpi et al. 2011; Helldán et al. 2013; Borodulin et al. 2014), although the increase 
in BMI has slowed down  in men and the BMI of women has stayed constant during the past 
22 Review of the Literature 
few years (Borodulin et al. 2014). This similar, favorable trend has also been observed in 
United States (Flegal and Carroll 2010). The major concern is the increasing overweight of 
younger people (National Institute for Health and Welfare; Ogden et al. 2014). Large regional 
differences in BMI are also present (Borodulin et al. 2014) and overweight is more common 
in the western part of Finland (Southern Ostrobothnia) than in the whole of Finland (Helakorpi 
et al. 2011; Hietaranta-Luoma et al. 2011; Helldán et al. 2013).    
Dyslipidemia (high serum lipids) 
Dyslipidaemia can be defined as a disorder where there is an abnormal amount of lipids in 
the blood (Koriyama et al. 2012). These lipids include Low Density Lipoprotein (LDL), High 
Density Lipoprotein (HDL) and Triglycerides (Tg). The total cholesterol consists of these 
three lipids (LDL, HDL and Tg). Reference values (Finland) for total cholesterol is under 5.0 
mmol/l, for LDL cholesterol under 3.0 mmol/l, triglyceride content under 1.7 mmol/l, HDL 
cholesterol over 1.0 mmol/l (men) and over 1.3 mmol/l (women) (Tarnanen et al. 2013). The 
American Heart Association and National Institute of Health have also set recommended cho-
lesterol and triglyceride levels: the recommended total cholesterol is under 5.2 mmol/l (200 
mg/dL) and HDL cholesterol is over 1.03 mmol/l (60 mg/dL), optimal LDL cholesterol is 
under 2.6 mmol/l (100 mg/dL) and triglyceride content under 1.7 mmol/l (151 mg/dL) 
(American Heart Association; National Institute of Health). 
There is a considerable amount of data demonstrating that dyslipidaemia increases the 
risk for CVD and the link between high serum lipids and CVD have been accepted worldwide 
(Koriyama et al. 2012). The worldwide MRFIT – project (Multiple Risk Factor Intervention 
Trial) for 350 000 middle-aged men, demonstrated a clear positive correlation between total 
serum cholesterol (over 240 mg/dl) and coronary risk ratio (Stamler et al. 1986). Dietary as-
pects and physical activity have a central role in serum lipids (discussed later in this disserta-
tion in the chapter on dietary aspects and physical activity) (Koriyama et al. 2012). 
Over the past few years, the total cholesterol has started to increase again in Finland 
after the remarkably favourable change since 1970s (Borodulin et al. 2014). A similar trend 
has also been observed in Sweden between 2008 and 2010 (Ng et al. 2012). The pooled total 
cholesterol mean in 2007 was 5.36 mmol/l in men and 5.14 mmol/l in women. After five years 
(2012) the corresponding values were 5.43 mmol/l in men and 5.29 mmol/l in women. The 
only area where total cholesterol has continued to decrease during the last five years was in 
Helsinki/Vantaa and this trend was only in men. (Borodulin et al. 2014) 
Hypertension (high blood pressure) 
Hypertension is defined as disorder where the pressure in the arteries that carry blood from 
the heart to the rest of the body is too high. Blood pressure is divided into systolic blood 
pressure and diastolic blood pressure. The systolic blood pressure is the pressure in the arteries 
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as the heart contracts and the diastolic pressure is the pressure in the arteries as the heart 
relaxes.  Normal blood pressure is 130/85 mmHg or under, blood pressure between 130/85 
mmHg - 140/90 mmHg is satisfactory, but needs checking once a year and a blood pressure 
of 140/90 mmHg or above is at a raised level. (Duodecim and Suomen Verenpaineyhdistys 
2009, käypähoitosuositukset) 
It is well known that elevated blood pressure is related to increased risk of cardiovascu-
lar disease and mortality (Kannel 1995; van den Hoogen et al. 2000; Zhang et al. 2006). The 
study by Kannel et al. (1995) estimated that hypertension increases the risk of CVD to 2 to 3 
fold compared with the normal blood pressure (Kannel 1995). 
Hypertension with the diabetes has been noticed to further increase the risk of CVD 
(Strong Heart Study,12 years follow-up) (Zhang et al. 2006).  
Trends in Finland have been favorable in systolic blood pressure, but over the past few 
years (2007 – 2012) the diastolic blood pressure has increased both in men and women, being 
over the recommended level in men (85.5 mmHg) (year 2012) (Borodulin et al. 2014). Alt-
hough the diastolic blood pressure has decreased dramatically over the past forty-five years, 
it is still over the recommended level in men (134.4 mm/Hg) (Borodulin et al. 2014). 
Smoking 
Smoking is a well-recognized health risk. Further, it affects cardiovascular and cancer mor-
bidity and also causes abdominal obesity, and increases the risk for type 2 diabetes (Barrett-
Connor and Khaw 1989; Marti et al. 1991; Canoy et al. 2005; Patja et al. 2005). As described 
previously in this dissertation (chapter obesity), smoking has been observed to increase CVD 
risk together the obesity (Jonsson et al. 2002). Daily smoking has decreased in Finland, in the 
last few years. The change has been favorably dramatic in men over the past decades. In 
women, smoking has increased until 2002 and decreased after that (Borodulin et al. 2014).  
From men, 19 % and from women 13 % smoked daily in year 2012 (Helldán et al. 2013).  
Dietary aspects 
Diet has a major role in the prevention of lifestyle-related diseases, such as cardiovascular 
diseases (Mente et al. 2009). The occurrence of dyslipidaemia is mainly affected by dietary 
composition, especially dietary fat quality, smoking, blood pressure, and body mass index 
(Koriyama et al. 2012).The Finnish nutrition recommendations, compiled by the National 
Nutrition Council, gives comprehensive dietary guidelines and these recommendations are 
also suitable for preventing CVD (e.g. decrease cholesterol level or blood pressure) 
(Fogelholm et al. 2014). However, there are recommendations with a little more detailed for 
the people, who already have CVD and these guidelines are compiled by the Finnish Heart 
Association (Finnish Heart Association 2015). 
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The Finnish nutrition recommendations follow the ‘plate model’ and ‘food triangle’, in 
which the foundational and largest level consist of vegetables, fruits and berries and the top 
of the triangle consist of delicacies (e.g. snacks, candies, sausages, pizza, biscuits). The 
amount of saturated fat should be under 10 E% and at least 500 g vegetables, fruits and berries 
should be include in the daily diet. In addition, in order to keep the blood pressure within a 
normal range (≤130/85 mmHg), the daily salt intake should be only 5g. The wholegrain prod-
ucts (e.g. low-salt bread), potatoes and non-fat or low-fat dairy products should include in the 
daily diet. Fish is recommended to be eaten 2-3 times in week and the intake of low-fat/salt 
red meat (e.g. bovine, swine, and sheep) is not more than 500 g in a week. Bread is recom-
mended to be spread with vegetable-based margarine and oil-based dressing is recommended 
for salads. The diet should include only a little salt and sugar. (Fogelholm et al. 2014) 
There are several studies which have indicated the effects of dietary fat quality on serum 
lipids (Masson et al. 2003; Minihane et al. 2007; Ordovas et al. 2007). Excessive amounts of 
saturated fat and sugary foods indicate higher triglyceride values (Matikainen 2009). In addi-
tion, a high fiber diet (e.g. vegetables, berries and fruits + whole grain cereals) has shown to 
have favorable effects on total and LDL-cholesterol (Wood et al. 1983; Anderson 1985; 
Brown et al. 1999).   
Over the past decades, dietary composition (e.g. dietary fat quality, consumption of veg-
etables, fruits and berries and salt intake) has improved. However, in the last few years the 
trend has been the opposite, especially in dietary fat quality and salt intake (Fogelholm et al. 
2014). 
Excessive alcohol consumption is also one important risk factor for CVD, because it has 
been associated with the increased LDL cholesterol and triglyceride level, especially among 
APOE 4 carriers (Ordovas 2002; Matikainen 2009). There is evidence that moderate alcohol 
consumption (one proportion in a day) can protect against cardiovascular risk factors, but 
increased consumption (over 2 proportions in a day) clearly increases the risk for CVD 
(Ronksley et al. 2011). Excessive alcohol consumption has unfavorable effects on lipid me-
tabolism and blood pressure and it increases the risk of obesity (Lukasiewicz et al. 2005; 
Ronksley et al. 2011).  
Alcohol consumption increased dramatically between the years 1980 and 1990 in Fin-
land, but after that consumption has been constant in both men and women (Helldán et al. 
2013). In 2012, 38 % of men consumed at least eight doses of alcohol in a week and 27 % of 
women consumed five units of alcohol in a week (Helldán et al. 2013). 
Physical activity 
The development and compilation of the international and national guidelines for physical 
activity in adults (18-64) has been focus in past few years. (Anonymous. The Office of 
Disease Prevention and Health Promotion. 2008; Suomalaisen Lääkäriseuran Duodecimin 
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asettama työryhmä. 2012). Every kind of physical activity, which is regular, a moderate bur-
den, and takes at least 10 minutes is significant in terms of health. The Physical Activity 
Recommendation in Finland is to partake in endurance exercises at least twice a week, for 
least 30 minutes at the time (Suomalaisen Lääkäriseuran Duodecimin asettama työryhmä. 
2012; Fogelholm et al. 2014). In addition, physical activity, related to muscular condition is 
recommended twice a week (Suomalaisen Lääkäriseuran Duodecimin asettama työryhmä. 
2012; Fogelholm et al. 2014). Physical activity has a remarkable role in the prevention of 
CVD. Endurance exercise  especially, (e.g. walking, running, skiing, biking) promote health 
and prevent life-style related diseases (e.g. CVD and diabetes) (Fogelholm et al. 2014). In 
addition, regular physical activity affects the maintenance of normal weight and has favorable 
effects on serum lipids (Wood et al. 1983; Benzer et al. 1998).  Several favorable effects on 
mental health have also been found (Mason and Holt 2012), which can further affect the 
maintaining normal weight and prevent other cardiovascular risk factors. 
Although leisure-time physical activity has increased in Finland, other physical activity 
(e.g. exercise in work or work travel) has decreased (Peltonen et al. 2008; Helldán et al. 2013).  
2.5 Previous studies of utilizing genetic testing to achieve nutrition-and clinical 
related changes (Tables 2 and 3) 
Utilizing genotype-based health information and nutritional genetic testing purely to promote 
healthy lifestyles (e.g. diet, physical activity, and cholesterol) and prevent lifestyle-related 
diseases is quite a new research field and a very limited number of studies have been con-
ducted in this areas. This dissertation included an overview of only 16 studies between 2001 
and 2015 (Tables 2-3) and Marteau et al. (2010) included in their review only seven clinical 
studies. Both reviews found that the results were conflicting and the favorable changes lim-
ited.  Eight of the included studies in this dissertation review found significant favorable 
changes (e.g. intentions to eat healthy diet, increase vitamin and supplement intake, decrease 
sodium intake, weight reduction or controlling, increase vegetables consumption) (Frosch et 
al. 2005; Roberts et al. 2005; Smerecnik et al. 2007; Arkadianos et al. 2007a; Chao et al. 2008; 
Conradt et al. 2009; Vernarelli et al. 2010; Meisel et al. 2012; Egglestone et al. 2013; Meisel 
and Wardle 2014; Meisel et al. 2015 (Table 2-3). In addition, Marteau et al. (2010) observed 
that genetic information did not motivate people to stop smoking or increase exercising, but 
it may have some favorable effects on diet and lifestyle (Marteau et al. 2010a).   
No study about using genotype-based health information to prevent CVD, which con-
sidered the psychological, health behavioral, and clinical factors has been done before this 
dissertation study. Research into life-style related diseases is challenging as it is dependent 
on several genes and many lifestyle factors (e.g. dietary, physical activity, smoking), which 
affect interactions and therefore the disease risk. Partly because of this, most of the research 
has focused on testing the effects of genetic information to prevent cancers such as breast, 
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ovarian, lung, and colon cancers. Genetic information has, for example, motivated people to 
have more mammograms (Halbert et al. 2004; Watson et al. 2004; Collins et al. 2005; Claes 
et al. 2005; Kinney et al. 2005; McBride et al. 2010). O’neill et al. (2008) and Quach et al. 
(2009) studied  the effect of breast cancer (BC) genetic testing on dietary and physical activity 
and found no differences between the high-risk (BRCA 1/2+) or low-risk (BRCA 1/2-) group 
(O’Neill et al. 2008; Quach et al. 2009).   
Preventing obesity or weight management has been the most popular topic in the context 
of promoting healthy lifestyles with the genotyping (Harvey-Berino et al. 2001; Frosch et al. 
2005; Rief et al. 2007; Arkadianos et al. 2007b; Conradt et al. 2009; Meisel et al. 2012; Meisel 
and Wardle 2014; Wang et al. 2014; Meisel et al. 2015) (Table 2). Three of these studies 
found that positive obesity gene status did not affect BMI, weight, body fat percentage, fasting 
glucose, serum lipids, confidence or motivation to lose weight, or attitudes to eat a healthy 
diet in the short-term (<6 months) (Harvey-Berino et al. 2001; Rief et al. 2007; Conradt et al. 
2009) (Table 2). In Harvey-Berino et al. (2001) a pilot study of 30 obese women, obesity 
related gene (b3-adrenergic receptor) was screened and it was found that there was no differ-
ences in confidence to lose weight (p = 0.42) or in eating self-efficacy (p = 0.65) between the 
‘positive gene group’ and the ‘negative gene group’ after genetic feedback (Harvey-Berino et 
al. 2001). The study Rief et al. (2007) was conducted with 410 obese people and the results 
were compared between the two intervention groups: a ‘group, with counselling and genetic 
information’ and a ‘group with counselling, without genetic information’ and a control group. 
The study did not find any significant differences in BMI, restraint in eating, body acceptance, 
or self-efficacy between the groups after six months (Rief et al. 2007).  The Conradt et al. 
(2009) study was similar to the Rief et al. (2007) study, but they measured BMI, attitudes 
about weight loss goals, weight-related self-blame, coping, and body shame. They did not 
find any significant differences between the intervention groups, but a difference of (p<0.05) 
was found in the “likelihood of losing 5 % body weight” between the intervention and control 
groups and in “satisfaction with 5% weight loss” between the intervention group (without 
genetic information) and control group (Conradt et al. 2009). 
Short-term effects were found in the study by Frosch et al. (2004), which observed that 
imaginary, genetic susceptibility to obesity indicated stronger intentions to eat a healthy diet 
(p = 0.02) and in the study by Meisel et  al. (2015), it was noticed that the ‘intervention group, 
with genetic feedback’ had significantly higher thoughts (p = 0.003) about or had started con-
trolling their weight compared with the ‘control group, with only advice’ (Frosch et al. 2005; 
Meisel et al. 2015).  
A long-term effect was found in the Arkadianos et al. (2007)  study, which observed 
that nutrigenetic tests affected BMI reduction over  a 300 day period (Arkadianos et al. 2007b) 
(Table 2). This Arkadianos et al. (2007) study is good example of the importance of longer 
follow-up.  BMI reduction was quite similar in both groups (non-tested group and nutrigenetic 
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test group) during first 300 days. After 300 days, the BMI increased in both groups, but the 
increase was clearly greater in the non-tested group (3.25 kg/m2) compared with the tested 
group (0.65 kg/m2 (p = 0.023). Among the non-tested group, BMI was at the higher level after 
300 days compared with the baseline (weight as % of baseline: 103.2 % (non-tested group) 
and 95.6 % (nutrigenetics group). (Table 2) 
The other conditions or disease studied have been Alzheimer disease (AD), diabetes, 
Familial hypercholesterolemia (FH) and hypertension (Marteau et al. 2004; Roberts et al. 
2005; Chao et al. 2008; Taylor and Wu 2009; Vernarelli et al. 2010; Grant et al. 2013) (Table 
3). Chao et al. (2008), in their randomized, controlled, clinical testing (n = 53 (Ɛ4+ group), n 
= 58 (Ɛ4- group), n = 51 (control group)), for example, reported that the APOE4+ group had 
2.73 times more (p = 0.02) Alzheimer disease (AD) specific health behavior changes (in-
creased exercise, vitamin intake and dietary changes) compared with APOE4- group (Chao et 
al. 2008) (Table 3). On the contrary, Marteau et al. (2004) found in their randomized, clinical 
testing that the genetic testing of FH did not have an impact on smoking, diet, exercise, and 
medication adherence in three groups (mutation (n = 74), no mutation (n = 139) and no genetic 
diagnosis (n = 103)) 6 months after the diagnostic assessment. This study also found that 
cholesterol medication was considered more effective (p = 0.02) in lowering the cholesterol 
level than diet among the mutation group. (Marteau et al. 2004) (Table 3) However, the follow-
up period was longer (over one year) in the study of Chao et al. (2008) compared with the study of 
Marteau (2004) (six months), which may have had an effect on the more favorable results in the study 
of Chao et al. (2008). (Table 3) It has been shown that a longer and more intensive intervention period 
is more effective than a shorter and less intensive intervention when achieving a permanent lifestyle 
change (e.g. weight reduction, dietary changes) (Maderuelo-Fernandez et al. 2014; Wallace et al. 
2014). It is also possible that people consider Alzheimer disease a more severe condition and not as 
preventable as hypocholesteremia.  
The recent studies in the nutritional genetic testing field have been focused on utilizing 
or imitating the commercially direct-to-consumer genetic (DTC) testing in preventing life-
style related diseases (Bloss et al. 2011; Nielsen and El-Sohemy 2012; Bloss et al. 2013; 
Egglestone et al. 2013; Nielsen et al. 2014) (Table 3). This has brought new trends and pro-
gress into this research field, because these kinds of studies are much easier to conduct with-
out laborious clinical experiments and face-to-face consultation. However, it also brings some 
challenges and ethical problems, which have been discussed previously in this dissertation 
(Chapters 2.2.1 and 2.2.4). These DTC studies, included in this review consist of a wide spec-
trum of several life-style related genetic tests and assessments (e.g. dietary (salt-, fat-, fiber-, 
fruit- and vegetables consumption), physical activity, smoking, anxiety, test related distress, 
intention to complete the health behavior screening test and changes in perceptions of person-
alized nutrition) (Table 3). Their experimental design differs somewhat from ordinary, clini-
cal, nutritional genetic testing (e.g. all consultation is given by mail). Study of Nielsen & El-
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Sohemy (2012) and Nielsen et al. (2014), for example, was clinical, randomized and con-
trolled, including two groups (intervention group, n = 92, which received DNA-based dietary 
advice and control group, n = 46, which received only general dietary advice). Advice and 
consultations were only given by mail or electronically (Table 3). This study had similar ele-
ments to the experimental design of this dissertation study. Further, Bloss et al. (2011 & 2013) 
(n = 2037), Nielsen & El-Sohemy (2012) and Nielsen et al. (2014) (n = 138) did not observe 
any significant changes in nutritional-related outcomes between baseline and follow-ups (3 
months, 6 months (Bloss et.al), 12 months), when using genetic screening to impact on health 
behavior (Bloss et al. 2011; Nielsen and El-Sohemy 2012; Bloss et al. 2013; Nielsen et al. 
2014) (Table 3).	  However, on the contrary, the purely commercially direct-to-consumer ge-
nomic testing of Egglestone et al. (2013) showed that consumers, who had already received 
and completed the genetic testing (‘consumer group’, n = 189) had significantly better health 
behavior scores than potential consumers (n = 86), who were either considering the receiving 
or purchasing the test (Egglestone et al. 2013) (Table 3). The significant difference (p = 0.03) 
was in fruit and vegetables consumption between the 'consumer' group and 'potential consum-
er' group, as a sufficient fruit and vegetables intake was reported by 53.9 % of ‘consumer 
group, and 38.8 % of  ‘potential consumer’ group (Egglestone et al. 2013) (Table 3).  
The preventing life-style related diseases by genotype based health information is a new 
and growing research field and partly because of this there is great variation in the follow-up 
durations, methods, assessments and diseases or conditions which it is intended to prevent 
(Tables 2-3).  Only five studies of those included in this dissertation review had a follow-up 
period of over 10 months, seven of the studies used randomization, and only four studies 
included personal genetic counseling; this does not give a very convincing picture of these 
studies. However, based on the studies included, it can be concluded that genotype based 
information may have favorable effects on health promotion, but longer follow-ups and ge-
netic counseling must be included. Using genotype based health information to promote 
healthy lifestyles and prevent cardiovascular diseases is very challenging due to the many 
modifiable and non-modifiable risk factors and also the ethical aspects. However, this disser-
tation study aims to give one, unique view on this very recent, but gradually growing research 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































30 Review of the Literature 
 Aims of the Study 31 
3 AIMS OF THE STUDY 
The overall aim was to study how personalized genotype based health information affects an 
individual’s health. 
 
More specific objectives of the study were: 
1. To study the psychological effects of personal genetic information, provided by differ-
ent APOE genotypes, as a tool to promote lifestyle changes. (Paper I) 
2. To study the health behavioral and attitude effects of receiving personal genetic infor-
mation, using APOE genotypes as a tool for promoting lifestyle changes. (Paper II) 
3. To study the clinical (cardiovascular risk markers) effects of receiving personal genetic 
information, using APOE genotypes as a tool for promoting lifestyle changes. (Paper 
III) 
4. To study the associations between psychological-, health behavioral and clinical fac-






32 Material and Methods 
4 MATERIAL AND METHODS 
4.1 Project organization 
This one-year intervention study was part of the ‘Healthier food choices, tailored models for 
eating and exercises’ (TERVAS) project (2009 – 2012) in Southern Ostrobothnia, Finland. 
The study involved the University of Turku, the University of Vaasa, the Seinäjoki Central 
Hospital and Natural Resource Institute Finland (Luke; earlier MTT). Permission was re-
ceived from the Ethics Committee of the Central Hospital in Southern Ostrobothnia, Finland.  
The researcher group included a principal researcher, a medical doctor, a researcher of 
biotechnology, a certified nutritionist, a clinical chemist, professors of nutrigenomics, food 
science and consumer sciences and medical laboratory technologists. The managers of the 
study were Anu Hopia Professor of Food Science, University of Turku and Hannu Puolijoki 
Professor, Medical Doctor, the Central Hospital in Southern Ostrobothnia. The author was 
the principal researcher and she was responsible for the general coordination of the study, 
including planning of the practical implementation of the research and intervention activities, 
recruiting and advising assistants, and the design of the study questionnaires and forms in 
collaboration with the other members of the research team. 
4.2 Population and design (Papers I – IV) (Table 4 and Fig. 4) 
All the participants were healthy adults, aged 20 to 67 years and a major proportion of partic-
ipants had already previously participated in the TERVAS study through a questionnaire (n 
= 1706), which was randomly sent to 4,000 people in Southern Ostrobothnia. In this ques-
tionnaire, participants had the opportunity to report their willingness to participate in further 
studies; 520 people agreed to this further participation. Half of the participants were random-
ized into this intervention (n = 260). The first contact was made by telephone, when partici-
pants were asked whether they were willing to participate in the intervention along with ques-
tions about their demographic details and state of health. They were also given information 
about the study (schedule, measurements, genetic testing). Every participant who was identi-
fied as being on long-term medication (e.g., diabetes, cholesterol, blood pressure, psychiatric) 
or having a disease (e.g., diabetes, psychiatric) was excluded at this phase (n = 145). A minor 
proportion of the participants were recruited through newspaper advertisements (n = 36). (Ta-
ble 4, Fig. 4) 
Baseline interviews with all participants (n = 151) were conducted and the first meas-
urements were taken. In this baseline interview, their health state was screened, using a gen-
erally used form, which means that they were asked about any medication; diseases, and use 
of functional products which affect cholesterol absorption (e.g. plant stanols and sterols). 
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They were also asked about alcohol consumption, smoking habits, physical activity, and how 
they perceived their own health. In this first interview, the participants gave their written con-
sent to participate in the intervention. All participants had the opportunity to refuse to see 
their blood and gene results: no one refused.  
After these interviews, the participants  (n = 130) were given blood tests (including their 
serum’s lipids, blood glucose (0h and 2h), basic blood count (e.g. hemoglobin), the kidneys 
function (fP-Krea), liver (p-ALAT) and thyroid (P-TSH)),  and anthropometric  measure-
ments (e.g. blood pressure, Body Mass Index, waist circumference and body fat percentage). 
They also completed questionnaires on psychological factors (threat, anxiety, the stage of 
change) and behavioral factors (including diet, alcohol consumption, physical activity and 
health and taste attitudes). On the basis of the first interview (n = 21) and blood tests (n = 8), 
participants, who had long-term medication (e.g., diabetes, cholesterol, blood pressure, psy-
chiatric medication) or chronic conditions (e.g., diabetes or mental disorders) were excluded 
(n = 29). These people were directed to public health care. Other inclusion criteria included: 
blood pressure under 160/99 mm/Hg, hemoglobin over 120 g/l, proper kidney, liver and thy-
roid function (fP-Krea <115 umol; p-ALAT 10 – 35 U/I (women), 10 – 50 U/I (men);P-TSH 
0.30 – 4.20 mU/l). Individuals who were overweight (BMI 20 – 35 kg/m2), had slight hyper-
lipidemia (total cholesterol < 8 mmol/l, triglycerides < 4.5 mmol/l) or impaired glucose tol-
erance (fasting glucose < 7.0 mmol/l and glucose two hours after challenge < 11.0 mmol/l) 
were included in the study. After the first screening, the final number of participants for the 
intervention was 122. (Table 4, Fig. 4) 
After these first measurements (T0), all participants attended a lecture on healthy life-
style and diet held by a qualified nutritionist (chapter 4.2.3). 
This study was single-blinded as the principal researcher, and a medical doctor, followed 
the anxiety measurements of the participants. The participants (n = 122) were randomized 
into a control group (n = 61) and an intervention group (n = 61). 
After eight weeks, immediately after all genotype results were ready and available, the 
intervention groups (Ɛ4+ and Ɛ4-) received their APOE genotype information and health mes-
sage by mail. This information was sent together with a tailored health-risk message based on 
their APOE genotype (Table 5, chapter 4.2.4 Health messages, Appendix 1-8). The specific 
threat communicated to the participants was, in this case, CVD, and the effect of the APOE 
genotype on CVD was emphasized for each participant in the intervention groups.         
Within two weeks of receiving their messages and genotype information (T1), all par-
ticipants also received web-based questionnaires on psychological factors (e.g. threat and 
anxiety experiences, the stage of change) and behavioral factors (e.g. diet, physical activity, 
alcohol consumption, health and taste attitudes). (Table 4, Fig. 4). About two weeks was as-
sumed to be sufficient time for the participants to ponder the results, but not too long in order 
to be able to capture the first psychological responses (e.g. threat and anxiety experience). 
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After 12 weeks, all the participants were offered the opportunity to attend genetic coun-
seling and a lecture was given by a professor of nutrigenomics and nutrigenetics. At this point, 
the intervention group also had the possibility to have a personal discussion with a medical 
doctor. Seven people used this opportunity. (Chapter 4.2.3 Lectures and Consultations) After 
five months the health messages and gene information were repeated (Fig 4).  
At the six-month measurement point (T2), the participants were given blood tests (in-
cluding the cholesterol level, blood glucose (0 h) and basic blood picture) and other measure-
ments (e.g. Body Mass Index, fat percent, waist circumference, blood pressure). These meas-
urements were the same as those taken at the baseline, except for the gene tests and glucose 
tolerance 2-hours tests. At this phase of the intervention, participants again received web-
based questionnaires on behavioral factors (e.g. diet, alcohol consumption, physical activity 
and health and taste attitudes); this was before they took part in the six-month clinical meas-
urements. Psychological factors (e.g. threat, anxiety and the stage of change) were not gauged 
at this time. (Table 4, Fig. 4) 
The final measurements, after 12 months (T3), were very similar to the six-month meas-
urements (T2). In this phase participants (n = 117) took part in a glucose tolerance 2-hour test 
and answered questionnaires regarding threat, anxiety, and the stage of change. (Table 4, Fig. 
4) After 12 months, the control group also had the opportunity to obtain further information 
about their own APOE genotype and the opportunity to consult with a medical doctor. This 
session was similar to the intervention group. Three people used this opportunity for a per-
sonal discussion with a doctor. (Chapter 4.2.3 Lectures and consultation) 
Of all 122 participants, five people withdraw from the intervention, and participants who 
had started cholesterol, blood pressure or diabetes medication during the intervention were 
excluded (n = 4). There were 113 participants who completed the study. For the analyses, 
participants who had missing values in their answers (n = 4, (Papers I, II); n = 5 (Papers III, 
IV)) or transpired to be outliers were excluded (n = 2). Thus, results for 107 (Papers I, II) and 
106 (Papers III, IV) participants were analyzed. (Fig. 4) 
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Figure 4. General procedure of the intervention. 
#) There were 56 participants in the studies I and II and 55 participants in the studies III and IV. 
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Table 4. Schedule of measurements. 
 
 
4.2.1 Intervention groups 
There were two intervention groups: a high risk group (Ɛ4+), including individuals with the 
APOE genotype 3/4 or 4/4 and low risk group (Ɛ4-), including individuals with the APOE 
genotypes 2/3 and 3/3. Both intervention groups received their genetic information at the be-
ginning of the intervention. They received tailored health messages during the intervention 
and they had the opportunity to have a discussion with the doctor after the genetic feedback. 
Altogether, 51 participants remained in the intervention: 16 in high-risk group and 35 in low-
risk group. Genotypes APOE 3/4 (n = 15) and 4/4 (n = 1) were included in group Ɛ4+ and 
genotypes 2/3 (n = 8) and 3/3 (n = 27) were included in group Ɛ4-. 
4.2.2 Control group 
At the beginning of the intervention, 61 participants were randomized into a control group. 
Altogether, 56 (Papers I – II) and 55 (Papers III - IV) participants remained in the intervention. 
In the control group, the participants had genotypes 3/4 (n = 11), 4/4 (n = 1), 2/3 (n = 6), 3/3 
Baseline (T0) 10 weeks (T1)#) Six months (T2) 12 months (T3)
Baseline Interview x NM NM NM
ApoE gene test x NM NM NM
Psychological measurements x x NM x
     State Anxiety (A-State) x x NM x
     Trait Anxiety (A-Trait) x x (NA) NM x (NA)
     Threat x x NM x
     State of change x x NM x
Behavioral measurements x x x x
     Dietary fat quality x x x x
     Consumption of vegetables x x x x
     Consumption of high fat and sugar foods x x x x
     Consumption of alcohol x x x x
     Physical activity x x x x
     Health and taste attitude (HTAS) x x x x
Clinical measurements x NM x x
     Serum's lipids x NM x x
     Blood glucose (0h) x NM x x
     Blood glucose tolerance (2h) x NM NM x
     Blood pressure x NM x x
     Body Mass Index x NM x x
     body Fat Percentage x NM x x
     Waist circumference x NM x x
#) two weeks after receiving gene results.         
x (measured)
NM (not measured)
NA (not analyzed in statistically). A-Trait is personal property and it was only used as an background variable.
 Material and Methods 37 
(n = 37 (36)), and 2/2 (n = 1). The control group received their genetic information at the end 
of the intervention (after 12months). During the intervention, they received only general in-
formation about the study together with general health information on lifestyle and CVD risk, 
based on health and nutrition recommendations and studies from the National Institute for 
Health and Welfare, Finland. At the end of the intervention, they also had an opportunity to 
have a discussion with the medical doctor.   
4.2.3 Lectures and consultation 
The first communication session, held by a certified nutritionist was arranged on the same 
day as the first measurements (T0). This lecture was compulsory and the purpose of the lec-
ture was that every participant would have the same basic knowledge regarding a healthy diet 
and lifestyle. It was essential that participants would understand the importance of eating 
healthy food and the role APOE plays in cardiovascular health. During the lecture, it was 
emphasized that healthy choices are cornerstone factors for decreasing risks for lifestyle dis-
eases, such as CVD, and that genomics have a limited role in increasing or decreasing risks 
for lifestyle diseases. In addition, the connection between the APOE gene to Alzheimer dis-
ease (AD) was mentioned, due to ethical reasons (APOE 4 allele increases the risk to having 
AD). However, the aim was to focus on the role of APOE in cardiovascular health. 
The second communication session was arranged after the intervention group received 
their gene results (3 months after baseline).  This lecture was elective, held by a professor of 
nutrigenomics and it focused more on gene-diet interactions and function o of the APOE gene 
than the first lecture. Twenty nine participants attended this lecture (Fig. 4). 
Both groups (intervention and control group) also had an opportunity for a private dis-
cussion with a medical doctor about their blood- and gene test and how these results have 
affected them physically and mentally. The intervention group had this opportunity after the 
genetic feedback (3 months after baseline) and the control group had the same opportunity 
after the intervention (12 months after baseline). Seven participants from the intervention 
group (Ɛ4+ (n = 3), Ɛ4- (n = 4)) and three participants from the control group used this oppor-
tunity (Fig. 4). These personal discussions were arranged as recommended the Ethical com-
mittee. 
4.2.4 Health messages (Table 5, appendix 1-8) 
The health information (message) was based on the analyzed APOE genotype and it was per-
formed using the Extended Parallel Process Model (EPPM) (Witte 2001). The specific risk 
communicated to the participants in the study concerned CVD, and the effect of the APOE 
genotype on CVD risk was emphasized for each participant in the intervention groups by 
using one of the four different kinds of health messages. All the tailored health information 
comprised of four different parts: response efficacy, self-efficacy, susceptibility, and severity 
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(Witte 2001). The combinations of messages were high real threat + high experience threat, 
high real threat + low experience threat, low real threat + high experience threat, and low real 
threat + low experience threat. If people had a high CVD threat experience and they also had 
an actual threat (Ɛ4+), a health message was created to reassure and intensify self-efficacy 
and efficacy. Those, who lacked the threat of a risk of CVD and also experienced no actual 
threat (Ɛ4-), received a message, which aimed to inform these participants about the disease. 
Participants, who had high actual threat (Ɛ4+), but did not feel a threat as regards the received 
message, the message was aimed to add susceptibility. The message for participants, who had 
a high threat feeling, but no actual threat (Ɛ4-) comprised items about increasing self-efficacy 
and susceptibility. 
In practical terms, the message for the Ɛ4+ group emphasized that a dietary change (e.g., 
improvement of fat quality) and increased exercise would be especially important for their 
genotype in order to lower the cholesterol level and prevent CVD. The information for the 
Ɛ4- group emphasized the interaction between environmental factors and the genotype and 
highlighted the significance of the individual’s own lifestyle. The control group received only 
general information about the study together with general health information on lifestyle and 
CVD risk, based on health and nutrition recommendations and studies from the National In-
stitute for Health and Welfare, Finland. This message did not consider the APOE genotype or 
threat experience.  
Table 5. Health messages. 
 
 
Group Based Model Specific Risk Aim Example







To emphasize the importance 
of the genotype on influencing 
dietary changes (e.g., 
improvement of fat quality) 
and increasing exercise to 
lower cholesterol level to 
prevent CVD
"…you have apoE 3/4 genotype, 
which means that you have 
hereditary higher cholesterol and 
bigger risk to get CVD, but 
especially YOUR cholesterol has 
good response to lifestyle 
changes…"
Ɛ4- 
apoE  genotype 







To emphasize the interaction 
between environmental 
factors and the genotype and 
highlight the significance of 
the individuals' own lifestyle.
"…your apoE genotype doesn't 
increase risk to higher cholesterol 
and CVD, but apoE is only ONE 
factor - your own lifestyle has big 
weight preventing CVD…"
Control 
general health and 
nutrition 
recommendations 
and studies from 
the National 




To give general health 
information on lifestyle and 
CVD risk.
"…genome may predispose to CVD, 
but healthy diet, regular physical 
activity, minor alcohol consumption 
and maintenance normal BMI lower 
clearly the CVD risk…"
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4.2.5 Assessments of APOE genotype 
The whole blood samples at baseline for the APOE assay were taken at the South Ostrobothnia 
Central Hospital laboratory. Genomic DNA was extracted from the blood samples, as de-
scribed by (Miller et al. 1988). The genomic region containing two SNPs 
(rs429358:p.Cys130Arg and rs7412: p.Arg176Cys) was amplified using the primers 5’-GCC-
TACAAATCGGAACTGGA and 5’-ACGAGGTGAAGGAGCAGGT and sequenced with 
the MegaBACE 1000 (Amersham Biosciences, UK). The three major APOE isoforms were 
determined by these SNPs, which translate into the common (epsilon) protein isoforms ε2 
(130Cys/176Cys), ε3 (130Cys/176Arg), and ε4 (130Arg/176Arg). DNA extractions and gen-
otyping were conducted at the Natural Resource Institute Finland (Luke; earlier MTT). 
4.2.6 Psychological assessments (Paper I) 
The study participants completed three psychological assessments (T0, T1, T3) (Table 4) dur-
ing the intervention - their validated anxiety (State-Trait Anxiety Inventory, STAI), threat 
(Risk Behavior Diagnostic Scale, RBD) and stage of change (The Transtheoretical Model of 
Behavior Change) questionnaires (Spielberger C, Gorsuch RL 1970; Spielberger C 1971; 
Witte 2001; Prochaska JO 2005).  
STAI measures both State Anxiety and Trait Anxiety. The State Anxiety (A-State) is an 
emotional feeling for which the intensity may change under different circumstances and it 
describes the feelings at the moment. The Trait Anxiety (A-Trait) is a personal property, 
which differs among individuals and it describes general feelings. (Spielberger C, Gorsuch 
RL 1970; Spielberger C 1971).  
Threat experience, measured by RBD, describes the perceived Health Threat, which was 
related to cardiovascular diseases in the present study. It comprises items of Response Effi-
cacy, Self-Efficacy, Susceptibility and Severity. (Witte 2001)  
Stage of change describes a motivation for lifestyle change (“Have you considered a 
lifestyle change?”) and it comprises five stages: (1) pre-contemplation, (2) contemplation, (3) 
preparation, (4) action, and (5) maintenance (Prochaska JO 2005). In dissertation study in-
cluded the first four steps. 
4.2.7 Health behavioral assessments (Paper II) 
All the study participants were asked to answer five different health behavior questionnaires 
four times (T0, T1, T2, T3) during the intervention (Table 4). The dietary fat quality –assess-
ment was based on the questionnaire of the Finnish Heart Association (Finnish Heart 
Association 2010). This questionnaire has nine items and it describes how large a part of an 
individual’s diet has unsaturated and saturated fat. 
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In the questionnaire on vegetables, fruits, and berries questions were asked about the 
portions of these in daily consumption, and it was based on the National Institute of Health 
and Welfare, in Finland, and also the report of the FIN-D2-D project (Peltonen et al. 2008; 
Saaristo et al. 2009) 
Questions were asked about the weekly consumption of high fat/sugar. The foods were 
divided the six categories: pizza, hamburgers and kebab, salty pastries (e.g., meat pies), salty 
snacks (e.g., potato chips), sweet pastries (e.g., biscuits), chocolate, and candies. Sweetened 
beverages were also categorized into high sugar fruit drinks or high sugar soft drinks (e.g., 
Coca-Cola©). This questionnaire was created in cooperation with the research team and based 
on the report of National Institute for Health and Welfare, Finland (Helakorpi et al. 2008). 
The study participants were asked the frequency and weekly portions of alcohol con-
sumption and in addition the frequency of leisure time physical activity. These questionnaires 
were based on the report of the National Institute for Health and Welfare, Finland (Helakorpi 
et al. 2008).  
4.2.8 Health and taste attitude assessments (Paper II) 
The study participants completed the validated health and taste attitude questionnaires 
(HTAS) four times (T0, T1, T2, T3) during the intervention (Roininen et al. 2001). The HTAS 
measures the importance of the health and taste aspects in the food choice process and it 
consists of six different dimensions (1) general health interest, (2) light product interest, (3) 
natural product interest, (4) craving for sweet foods, (5) using food as a reward, and (6) pleas-
ure. The first three dimensions represent the health attitude, and the other three dimensions 
the taste attitude. (Roininen et al. 2001) (Table 4) 
4.2.9 Clinical assessments (Paper III) 
The clinical assessments were arranged three times (except two hours after challenge blood 
glucose test two times (T0, T3)) during the intervention: at the baseline (T0), after six months 
(T2) and at the end of the intervention (T3). Measurements were performed in the Department 
of Clinical Chemistry, at the Central Hospital of Southern Ostrobothnia, Finland. Blood sam-
ples and blood pressure (systolic/diastolic) were taken by medical laboratory technicians. 
Metabolic Syndrome (MeS) was also assessed based on worldwide definitions (Alberti et al. 
2005). (Table 4) 
Serum lipids (total-, LDL-, HDL cholesterol, triglycerides) and blood glucose (fasting 
glucose (0h), 2 h after challenge (2h)) were analyzed according to standard guidelines by 
enzymatic photometry, The Architect c8200 analyzer (Abbot Diagnostic, Abbot Park, IL, 
USA).  
Blood pressure was analyzed with using an oscillometric method, i.e., two measure-
ments, in a sitting position, using the right arm, after 15 minutes of rest.  
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Anthropometric analyses (Body Mass Index, body fat percentage) were conducted by 
Body Composition Meter (Omron BF 500). Weight was analyzed with light indoor clothes, 
and height without shoes. Waist circumference was measured by a measuring tape, midway 
between the lowest rib and the iliac crest. 
For the inclusion/exclusion of the participants, the Complete Blood Count (CBC) (Sys-
mex XE-5000, Kobe, Japan) and the kidney function (fP-Krea), liver (p-ALAT) and thyroid 
(P-TSH) were assayed in a baseline (T0). 
4.2.10 Explained changes and predictors (Paper IV) 
Study IV combined the results of the three previous Papers (I, II, III) by analyzing associations 
between psychological-, behavioral- and clinical changes. It focused on explaining the 
changes, which were statistically clearest in the previous studies (I, II, III). The changes were 
cardiovascular threat experience (T0-T1), based on Risk Behavior Diagnostic Scale (RBD) 
(Witte 2001), dietary fat quality (T0-T1) based on questionnaire of Finnish Heart Association 
(Finnish Heart Association 2010), triglyceride values (T0-T2) based on standard guidelines 
by enzymatic photometry, The Architect c8200 analyzer (Abbot Diagnostic, Abbot Park, IL, 
USA) and waist circumference (T0-T2) based on tape measurements, midway between the 
lowest rib and iliac crest. 
Predictors, were included in the analysis in following order, group (Ɛ4+, Ɛ4-, control), 
sex, age, psychological assessments (Trait-Anxiety (T0), State Anxiety (T0-T1), stage of 
change (T0-T1), behavioral assessments (T0-T1; dietary fat quality, consumption of vegeta-
bles, consumption of high fat and sugar foods, consumption of alcohol, physical activity), 
attitude assessments (T0-T1; health and taste attitude (HTAS (Roininen et al. 2001)) and clin-
ical assessments (T0-T2; Total-, LDL- HDL cholesterol, blood glucose (0h), blood pressure, 
Body Mass Index, body Fat Percentage,). In addition, the explained changes (threat experi-
ence, dietary fat quality, triglyceride values and waist circumference) were included as pre-
dictors, when explaining the other changes that were statistically clearest. 
4.2.11 Statistical methods 
Data management and analysis were performed using SPSS (IBM) Corp. Released 2012. IBM 
SPSS Statistics for Windows, Version 21.0 Armonk, NY: IBM Corp. In Papers I-III, the pre-
liminary analyses (exploring normality, missing values, and outliers) were done before the 
final analyses. Normality was analyzed from residuals with the Kolmogorov-Smirnov method 
and histograms. Variables, (State-anxiety, dietary fat quality, consumption of high fat/sugar 
foods, and alcohol, BMI and waist circumference) which were not normally distributed were 
transformed and modified. The main variables were adjusted for their own baseline scores 
(T0) by covariance analyses. In addition state-anxiety was adjusted for trait-anxiety. 
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In Papers I-III, the main effects of the adjusted scores were analyzed by a mixed be-
tween-within subject analysis of variance (a combination of repeated-measures ANOVA and 
a between-groups ANOVA; General linear models, repeated measures). A Chi-Square –test 
was used to analyze the frequencies. Pairwise comparisons were conducted using the Bonfer-
roni method. The effects of the lecture and personal discussions with the doctor at measuring 
point T3 were analyzed using covariance analyses (one-way ANCOVA).   
In Paper IV, changes (∆) between T0 and T1/T2 measuring points were calculated. 
Changes (∆) between T0 and T1/T2 measuring points were calculated. Preliminary analysis 
(exploring normality, multicollinearity, missing values and outliers) were done before final 
analyses.  Hierarchical multiple regression was used to analyze predictors for the changes in 
threat experience, dietary fat quality, triglyceride values and waist circumference. In regres-
sion analysis, the variable indicating the group (Ɛ4+, Ɛ4-, control) was forced into the model 
after which a forward stepwise method was used to find out the statistically strongest predic-
tors (models (a) to (c)).   
Randomization and the power analysis 
The included participants (n = 122) were randomized into a control group and an intervention 
group. The randomization was done by using the random sampling method of Microsoft Ex-
cel. Participants who received the first 61 random numbers were put into the intervention 
group and the remaining 61 participants were put into the control group. The randomization 
was done before genotype results were available, so the intervention group sizes differed. 
This difference was purely due to the number of carriers with APOE 3/4 and 4/4. 
Effect sizes (Partial Eta Squared) and observed power were analyzed by SPSS program. 
Statistical power analysis was conducted by G*Power program (Faul et al. 2007). It was done 
after the intervention, when analyzing results. Based on the power analysis, F-test (sensitivity) 
was used to calculate minimum, detectable effect sizes with the power of 0.80 and the appro-
priate F-test for the main variables was ANOVA (Repeated measures, between factors) and 
for the effects of lecture and discussion and A-Trait ANCOVA (Main effects and interac-
tions).  
The effect sizes (f) were for the main variables (A-State, threat, stage of change) 0.190 
and for analyses of covariates (the effects of lecture and discussion and A-Trait) 0.275.   
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5 RESULTS 
5.1 Baseline results (Papers I – IV) (Table 6 and 7) 
Altogether 113 individuals completed the study of which the psychological and behavioral 
factors were analyzed for 107 participants and the clinical factors for 106 participants. Of the 
total of 107 (106) individuals who were analyzed, 69.2 percent were females, with a mean 
age of 47.0 (standard deviation, S.D.: 12.1) years (range: 20–67 years). There were significant 
differences (p < 0.001) in the age between the women and the men who participated in the 
study (women: 44.2 years (S.D.: 11.4) versus men: 53.3 years (S.D.: 11.4)). (Table 6) 
Approximately one-fourth (26.2%) of the participants had an E4 allele (3/4, 4/4) placing 
them at an increased risk for CVD. Sixteen participants with the high-risk genotype (APOE 
3/4, 4/4) were randomized in the high-risk intervention group and 12 participants in the con-
trol group. Thirty-five participants with the low risk genotype (APOE 2/3, 3/3, 2/2) were in 
the low-risk intervention group and 44 in the control group. Differences between the groups 
were not significant. (Table 6) 
The A-Trait was mild (Spielberger C, Gorsuch RL, Lushene PR, Vagg Pra 1983); ap-
proximately 31.7 and varied between 21 and 50. (Table 6) 
Clinical measurements were also analyzed at the baseline between the different APOE 
genotypes. The total population (n = 106) was divided into two groups: APOE 4+ (n = 28), 
including participants with the APOE 3/4 and 4/4 genotypes and APOE4- (n = 78), including 
APOE 2/2, 2/3 and 3/3 genotypes. Mean total cholesterol was 5.20 mmol/l, LDL cholesterol 
3.10 mmol/l, HDL cholesterol 1.52 mmol/l and triglycerides 1.18 mmol/l. Average body mass 
index was 25.8 kg/m2. (Table 7) The metabolic syndrome (Alberti et al. 2005) was present in 
18.9 % of the total participants and 24.2 % of the men and 16.4 % of the women. 
The differences between the groups (APOE4+ and APOE4-) were minor at the baseline. 
The APOE4+ group had a higher total, LDL and HDL cholesterol than the APOE4- group 
and correspondingly the APOE4- group had higher triglyceride content, blood glucose (0h 
and 2h), blood pressure (systolic and diastolic), BMI, fat percent, and waist circumference 
than the APOE4+ group. The only significant difference was in body fat percentage (p = 
0.003) as it was 28.5 % in APOE4+ group and 33.9 % in APOE4- group. (Table 7) 
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Table 6. Demographics and background variables of included (107/106) participants. 
 
Table 7. Comparison of baseline clinical measurements between the APOE4+ (3/4, 4/4) and APOE4- group 
(2/2, 2/3, 3/3). 
 
 
Total Ɛ4+ group Ɛ4- group Control group
Number of  participants (n)#) 107 (106) 16 35 56 (55)
Age (years, mean (SD)) 47.0 (12.1) 47.8 (12.3) 47.3 (11.2) 46.7 (12.9)
          Men (years, mean (SD)) 53.3 (11.4)
***)
          Women (years, mean (SD)) 44.2 (11.4)
Female, sex %, (n) 69.2 (74) 62.5 (10) 85.7(30)*) 60.7(34)*)
ApoE genotype %, (n)
          E3/E3     59.8 (64) 0 (0) 77.1 (27) 66.1 (37)
          E3/E4     24.3 (26) 93.8 (15) 0 (0) 19.6 (11)
          E2/E3 13.1 (14) 0 (0) 22.9 (8) 10.7 (6)
          E4/E4 1.9 (2) 6.2 (1) 0 (0) 1.8 (1)
          E2/E2 0.9 (1) 0 (0) 0 (0) 1.8 (1)
Trait-Anxiety (mean (SD)) 31.7 (6.5) 33.7 (7.9) 30.3 (5.9) 31.9 (6.5)
          Moderate anxiety % (n) 12.3 (13) 18.8 (3) 8.8 (3) 12.5 (7)
Participants in personal disscussion % (n) 9.3 (10) 18.8 (3) 11.4 (4) 5.4 (3)
Partipants in the lecture of nutrigenomics % (n) 27.1 (29) 56.3 (9) 17.1 (6) 25.0 (14)
#) In studies I and II included in 107 participants and in studies III and IV included in 106 participants.
*) p<0.05
***) p<0.001
Total ApoE 4+ group (n = 28) ApoE 4- group (n = 78)
Measurement Mean (SD) (baseline) Mean (SD) (baseline) Mean (SD) (baseline)
Total cholesterol (mmol/l) 5.20 (0.95) 5.26 (0.90) 5.15 (0.96)
LDL cholesterol (mmol/l) 3.10 (0.81) 3.26 (0.74) 3.07 (0.83)
HDL cholesterol(mmol/l) 1.52 (0.35) 1.52 (0.40) 1.52 (0.33)
Triglycerides (mmo/l) 1.18 (0.60) 1.06 (0.55) 1.22 (0.61)
Blood glucose (0h) (mmol/l) 5.50 (0.43) 5.48 (0.45) 5.53 (0.42)
Blood glucose (2h) (mmol/l) 5.90(1.32) 5.52 (1.33) 5.98 (1.30)
Blood pressure, systolic (mmHg) 129.3 (16.6) 127.0 (17.4) 130.1 (16.4)
Blood pressure, diastolic  (mmHg) 77.1 (9.0) 75.8 (9.2) 77.6 (8.9)
Body Mass Index (BMI) (kg/m2) 25.8 (3.8) 24.7 (3.0) 26.1 (4.0)
body Fat Percentage (%) 32.5 (8.2) 28.5 (6.8)**) 33.9 (8.3)**)
Waist circumference (cm) 85.9 (11.2) 84.2 (10.6) 86.6 (11.4)
**) p<0.01
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5.2 Intervention results (Papers I – III) 
The intervention had some effects on psychological, health behavioral and clinical factors. 
The effects were both short-term and long-term. 
5.2.1 Psychological results (Paper I, Fig. 5) 
State Anxiety 
State anxiety (A-State) was mild (Spielberger C, Gorsuch RL 1970; Spielberger C 1971)  in 
every group at every measurement point and varied from 27.9 to 36.1. The adjusted baseline 
scores were 30.8 in every group (Paper I). The A-State increased during the first 10 weeks in 
the Ɛ4+ (∆+3.1) and control (∆+2.2) groups, but decreased in both groups (Ɛ4+ group, ∆-1.5; 
control group ∆-0.1) during the last 10 months, although remaining at a higher level than at 
the baseline. In the Ɛ4− group, the A-State decreased (∆-0.1) after genetic feedback, but in-
creased (∆+1.1) between the measuring points T1 and T3. Experience of the A-State was 
significantly different in every group at the T0 measuring point compared with T1 measuring 
point (p=0.006) (Paper I). However, throughout the intervention period (12 months), there 
were no significant differences between the groups in their experiences of the A-State, alt-
hough the trend in Ɛ4− was opposite to the Ɛ4+group and control groups (Paper I, Fig. 5).  
Threat experience 
Every group had positive scores for the threat experience, which means that none of the groups 
felt any fear towards CVD (Witte et al. 2001) (Paper I). The mean threat experience among the 
total population was 5.0 (S.D.: 7.1) at the baseline. The adjusted baseline scores were 5.0 in 
every group (Paper I). Threat was experienced most strongly by the Ɛ4+group (∆-3.5) after they 
had received their personal genetic information, but it decreased (∆+1.5) after 12 months, alt-
hough remaining at a higher level than at the baseline (T0). Threat experience decreased in the 
Ɛ4− group (∆+2.0) after the first 10 weeks, but increased (∆-0.3) a little towards the 12 months 
period. In the control group, the changes were similar to those in the Ɛ4+group, but were smaller 
(T0-T1: ∆-0.8; T1-T3: ∆+1.5).  (Paper I; Fig. 5). There was almost no significant difference 
(alpha value 0.017) between the Ɛ4+ and Ɛ4− groups as regards threat experience (p=0.034) 
(Paper I). At the T3 measurement point, the threat experience was still at a higher level in 
Ɛ4+group (2.5) than in Ɛ4− group (6.7) and control group (5.7) (Paper I; Fig. 5). NOTE. In the 
threat experience, the lower the scores, the higher the threat experience. 
Stage of change 
At the start of the intervention, every group was on average at stage 2 (contemplation, getting 
ready, consider lifestyle change within the next 6 months) and after the intervention each of 
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the groups were at stage 3 (preparation, ready, have planned lifestyle change within next 
month) (Fig. 5, Paper I). The stage of change was significantly different at the baseline (T0) 
compared with T1 and T3 measuring points (p<0.001) in every group (Paper I). The greatest 
change was in the Ɛ4+group (ΔT0-T1), but the differences were minor and there were no 




Figure 5. Changes in state anxiety, threat experience, and stage of change during the inter-
vention.  
*) p = 0.034 (alpha value 0.017)  
NOTE. In threat experience, the lower the scores, the higher the threat experience.  
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5.2.2 Health behavioral results (Paper II, Fig. 6 and 7) 
Dietary fat quality 
Saturated fat intake was higher than recommended, belonging to the category ‘most of dietary 
fat was saturated and only a minor part unsaturated’, scores: 10-17 (Finnish Heart 
Association 2010) in every group (adjusted scores 16.3) (Paper II, Fig. 6). The intake of un-
saturated fat increased and saturated fat decreased in every group after the genetic feedback 
(T1). The change was greatest in the Ɛ4+ group (ΔT0–T1: +3.8), and there was a statistically 
significant difference between the Ɛ4+ and the control group (p = 0.048) (Paper II). Towards 
the end of the intervention and during the last 6 months with no active health communication 
(T3), the intake of saturated fat again increased and unsaturated fat decreased in both inter-
vention groups. This unfavorable change in scores was higher in the Ɛ4+ group (ΔT2–T3: –
1.7) than in the Ɛ4– group (ΔT2–T3: –0.2). In the control group, fat quality improved slightly 
even during the last 6 months of the intervention (ΔT2–T3: +0.2) (Paper II). Although the 
dietary fat quality deteriorated during the last 6 months of the intervention, the fat quality of 
the diet was improved at the end of the intervention (T3) compared with the baseline values 
(T0) for every group (Paper II, Fig. 6). Dietary fat scores were 18.7 (Ɛ4+ group), 18.3 (Ɛ4- 
group) and 17.8 (control group) after the 12 months (T3), this score belongs to the category 
‘acceptable in terms of fat quality and amount of unsaturated fat, scores: 18-22 (Finnish Heart 
Association 2010). However, this total improvement (T0–T3) was not significant in any 
group. (Paper II) 
Consumption of vegetables, fruits and berries, foods containing excessive fat and sugar 
and alcohol 
The average vegetable, berry and fruit consumption at the baseline was 2.3 portions a day, 
which is below the recommended level in Finland (at least five portions in a day, one portion 
being for example 1 apple or handful of carrot pieces) (Paper II).  Vegetable, fruit, and berry 
consumption increased slightly in every group during the intervention, being highest after six 
months (Ɛ4+ group: 3.0 portions, Ɛ4- group 3.0 portions and control group: 2.6 portions) (Pa-
per II, Fig. 6). However, the differences between the groups were minor and not statistically 
significant (Paper II).  
Mean consumption of foods containing excessive fat and sugar was 9.9 times/week at 
the baseline (Paper II). There was a decreasing trend in the consumption of foods containing 
excessive fat and sugar during the first 10 weeks (T1) in every group, being 8.2 times/week 
in Ɛ4+ group, 8.4 times/week in Ɛ4- group and 9.6 times/week in control group (Paper II, Fig. 
6). After six (T2) and 12 months (T3), their consumption increased nearly to the baseline level 
of the Ɛ4+ group (9.0 times/week), but in the Ɛ4- group the consumption decreased further 
during the later six month period, being 6.7 times/week (T3) (Paper II, Fig. 6). Consumption 
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was 8.8 times/week in the control group after 12 months (12). The total decrease (T0-T3) of 
foods containing excessive fat and sugar was significantly different in Ɛ4- group compared 
with the control group (p<0.05). (Paper II) 
The alcohol consumption was moderate during the intervention, being 2.4 doses/week 
at the baseline in every group (adjusted scores) and after 12 months 2.3 (Ɛ4+ group), 2.6 (Ɛ4- 
group) and 2.7 (control group) doses/week (Paper II, Fig. 6). At the baseline, alcohol was 
consumed the most (at least twice a week) by the control group (42.9 %) and the least by the 
Ɛ4+ group (18.8 %) (Paper II, Fig. 7). Of the participants in the Ɛ4- group 34.3 % consumed 
alcohol at least twice a week at the baseline (Paper II, Fig. 7). However, the changes in alcohol 
consumption after the disclosure of personal genetic information were minor, and there were 
no statistically significant differences between the groups (Paper II). 
Leisure-time physical activity 
Leisure-time physical activity (at least two times in a week) at the baseline was engaged in 
by 75.0 % of participants in the Ɛ4+ group, 80.0 % of Ɛ4- group and 66.1 % of control group 
(Paper II, Fig. 7).  Genetic feedback had only a minor impact on physical activity. The greatest 
difference was ΔT0–T1 between the Ɛ4+ and the Ɛ4– group. Physical activity increased by 
6.3% in the Ɛ4+ group but decreased by 17.1% in the Ɛ4– group; however, the difference was 






































































        Figure 6. Changes in health behavior factors during the intervention 
        *) p = 0.48, #) two weeks after genetic feedback 
        NOTE. Detailed scores and statistical tests have presented in Paper II.  
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Figure 7. Changes in alcohol consumption and leisure time physical activity frequencies  
during the intervention. 
#) two weeks after genetic feedback 
5.2.3 Health and taste attitudes results (Paper II, Fig. 8) 
Both health attitudes (general health interest, light product interest, and natural product inter-
est) and taste attitudes (craving for sweet foods, using food as a reward, and pleasure) were 
above average (health attitudes range 20 – 160; taste attitude range 18 – 126) in the baseline 
in every group (health attitudes scores: 90.4 and taste scores: 73.9) (Paper II).  
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In every group, there was an increasing trend toward the valuation of health (T0-T1: 
∆+8.3 (Ɛ4+), ∆+2.1 (Ɛ4-) and ∆+4.0 (control group) and a decreasing trend toward the valu-
ation of taste (T0-T1: ∆-2.3 (Ɛ4+), ∆-2.3 (Ɛ4-) and ∆-1.2 (control group) after the genetic 
feedback (T1) (Paper II, Fig. 8). However, especially later after a six months period, the val-
uation of health decreased slightly in both intervention groups (T2-T3: ∆-2.2 (Ɛ4+) and ∆-1.4 
(Ɛ4-) (Paper II, Fig. 8). In the control group, it stayed constant (94.4) during the later 10 
months period. The taste scores decreased further during the later six months period (T2-T3) 
in both intervention groups, being 67.2 in Ɛ4+ group and 70.7 in Ɛ4- group after 12 months 
(T3). Among the control group, the valuation of taste slightly increased (∆+1.0) and during 
the later six months period, was at a higher level (71.5) compared with intervention groups 
after 12 months (T3). (Paper II, Fig. 8) The taste attitude ‘pleasure’ was an exception as it 
increased slightly (T0-T1: ∆+0.1 (intervention groups) and ∆+0.2 (control groups) after ge-
netic feedback (T1) (Paper II). The clearest changes were among Ɛ4+ group, although there 
were no statistical significant differences between the groups (Paper II). 
 
 
Figure 8. Changes in health and taste attitudes during the intervention.  
NOTE. The health attitudes included general health interest, light product interest and natural product interest.  
The taste attitudes included craving for sweet foods, using food as a reward and pleasure. 
Detailed scores and statistical tests are presented in Paper II. #) two weeks after genetic feedback. 
5.2.4 Clinical results (Paper III, figures 9 – 11) 
The intervention had a trend toward a significant effect (p<0.05; alpha level 0.005) on two of 
the CVD risk markers (triglyceride values (p = 0.038) and waist circumference (p = 0.027)) 
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Society Duodecim 2013) at the baseline, in every group (1.18 mmol/l). The triglyceride con-
tent decreased more in the Ɛ4+ group (∆-0.30 mmol/l) compared with the Ɛ4- (∆-0.09 mmol/l) 
and the control group (∆-0.06 mmol/l) during the first six months (T0-T2). After a further six 
months (T2-T3), the triglyceride content had increased a little in the Ɛ4+ group (∆+0.02 
mmol/l), but decreased in the Ɛ4- (∆-0.01 mmol/l) and control group (∆-0.07 mmol/l).  De-
spite the differences, the triglyceride values were within the normal range (The Finnish 
Medical Society Duodecim 2013) in every group during the intervention. The average waist 
circumference was 86.1 cm at the baseline (adjusted). During the first six months (T0-T2), 
waist circumference shortened 2.5 cm in the Ɛ4+ group, 0.9 cm in Ɛ4- group, while it increased 
in the control group (∆+0.7 cm). In the control group, waist circumferences increased during 



























Figure 9. Changes in triglyceride content and waist circumference during the intervention. 
*) p = 0.038 (alpha level 0.005) in triglycerides; *) p = 0.027 (alpha level 0.005) in waist circumference  
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Favorable trends, but not close to a statistically significant effect were found in the fat 
percentage and systolic blood pressure in Ɛ4+ group. The fat percentage was 32.6 % in 
every group at the baseline. Among every group, fat percentage decreased during the first 
intensive communicating period (T0-T2). The Ɛ4+ group was the only group who improved 
their fat percentage during the last silent period (T2 – T3). The fat percentages were 30.1 % 
(Ɛ4+ group), 32.3 % (Ɛ4- group) and 32.6 % (control group) after 12 months (T3). Systolic 
blood pressure was at the recommended level (Duodecim and Suomen Verenpaineyhdistys 
2009) at the baseline in every group (128.9 mmHg). It decreased in the Ɛ4+ (∆-5.3 mmHg) 
and control group (∆ -4.0 mmHg) after the first intensive period. During the later six month 
period, the systolic blood pressure stayed almost at the same decreased level.  (Paper III, Fig. 
10) 
A favorable, but parallel trend in every group was in the glucose after two hours chal-
lenge (2h). It was 5.9 mmol/l at the baseline and it decreased slightly in every group (Ɛ4+: ∆-
0.8 mmol/l; Ɛ4-: ∆-0.7 mmol/l and control: ∆-0.5 mmol/l) after 12 months (T3). (Paper III, 
Fig. 10) 
The change in diastolic blood pressure was unfavorable in every group, increasing 
during the first six months period (T0-T2) ∆+4.9 mmHg (Ɛ4+ group), ∆+6.6 mmHg (Ɛ4- 
group) and ∆+4.2 mmHg (control group). In the later six months period, it decreased a little 
in every group, although still staying at a higher level (Ɛ4+: 78.1 mmHg, Ɛ4-: 80.5 mmHg, 
control: 80.6 mmHg) compared to the baseline (77.2 mmHg). (Paper III, Fig. 10) 
The intervention had no effect on total-, LDL- and HDL cholesterol, fasting glucose 
(0h) and BMI. These CVD risk factors stayed almost constant during the intervention. HDL 
cholesterol (The Finnish Medical Society Duodecim 2013) and fasting glucose were within 
the normal range in every group. HDL cholesterol was 1.52 mmol/l (range during the inter-
vention 0.00 – 0.05 mmol/l) and fasting glucose (0 h) was 5.5 mmol/l (range during the inter-
vention -0.2 – 0.0 mmol/l). However, the total and LDL cholesterol (The Finnish Medical 
Society Duodecim 2013) and BMI (24.99 kg/m2) were slightly over the recommended level 
in every group. Total cholesterol was 5.2 mmol/l (range during the intervention 0.0 - 0.1 
mmol/l) and LDL cholesterol was 3.1 mmol/l (range during the intervention 0.1 – 0.2 mmol/l). 
The average body mass index was at the baseline 25.8 kg/m2 (adjusted). Overweight partici-
pants were more common in the present study (68 % of men and 53 % of women) compared 
with the total Finnish average (Helldán et al. 2013). Detailed scores and statics are presented 







































ure 10. Changes in body Fat Percentage, blood pressure and blood glucose (2h) during the 
intervention. 
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Metabolic Syndrome 
In every group, the prevalence of metabolic syndrome decreased during the first intensive 
communicating period (T0-T2), but increased again after the later silent period (T2-T3) (Fig. 
11).  
 
Figure 11. Frequency of Metabolic syndrome during the intervention (T0, T2, T3). 
NOTE. The criterion for the Metabolic Syndrome: waist circumference ≥94 cm (men) and ≥80 cm (women) and having 
at least two of the following health risks: 1) triglyceride content of serum over 1.7 mmol/l, 2) HDL cholesterol under 1.0 
mmol/l (men) or 1.3 mmol/l (women), 3) systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, 4) 
fasting glucose (0h) over 6.0 mmol/l or glucose after 2 hours challenge (2h) ≥7.8 mmol/l. 
5.3 Results of the predictors behind the significant changes (Paper IV, table 8, 
Fig. 12) 
Change (∆T0-T1) in threat experience was best explained by the model (c) (15.8 %; p = 
0.005) which included the group, change in systolic blood pressure (T0-T2) and change in 
total cholesterol (T0-T2). The strongest predictor was the systolic blood pressure (T0-T2) (9.4 
%; p = 0.007; β = 0.290) 
Dietary fat quality change (∆T0-T1) was best explained by the model (b) (16.0 %; p = 
0.002), which included the group and body fat percentage (T0-T2). The strongest predictor 
was the body fat percentage (9.3 %; p = 0.005; β = -0.307). 
Change (∆T0-T2) in waist circumference was best explained by the model (b) (28.8 
%; p < 0.001) which included the group and the BMI, the strongest predictor being the BMI 
(21.9 %; p < 0.001; β = 0.471). 
Change (∆T0-T2) in triglycerides was best explained by the model (c) (25.6 %; p < 
0.001), which included the group and the changes (T0-T2) in the Body mass index (BMI) and 
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The hierarchical regression analyses also revealed some statistically significant interac-
tion-effects on change in triglyceride values (Fig. 12). Triglycerides correlated negatively 
with the HDL cholesterol (r = -0.245, p<0.05) and positively with the BMI (r = 0.470, 
p<0.001). HDL cholesterol correlated with the total cholesterol (r = 0.422, p<0.001), which 
correlated further with the threat experience (r = 0.281, p<0.05). The Body fat percentage 
correlated with the BMI (r = 0.455, p<0.001) and also waist circumference had an effect on 
the BMI (r = 0.386, p<0.01). The group (Ɛ4+, Ɛ4- and control) also had an effect on waist 
circumference (r = 0.234, p<0.05). (Fig 12) 
Table11. Hierarchical multiple linear regression analysis. Predictors for changes in threat experience (T0-T1), 
dietary fat quality (T0-T1), triglycerides (T0-T2) and waist circumference (T0-T2). 
 
 
Figure 12. Partial correlations of changes (∆), based on hierarchical regression analyses.  
Possible interaction-effects on triglyceride values. *) p<0.05,**) p<0.01,***) p<0.001 
Explained change  
(dependent variable) Predictors Model R
2 p (R2) R2 Change p (change) β Single predictor
Model (a) 0.006 0.498 0.006 0.498 0.093 group
Model (b) 0.100 0.020 0.094 0.007 0.290 blood pressure, systolic
Model (c) 0.158 0.005 0.058 0.028 -0.242 total cholesterol
Model (a) 0.066 0.024 0.066 0.024 0.226 group
Model (b) 0.160 0.002 0.093 0.005 -0.307 body fat percentage
Model (a) 0.014 0.319 0.014 0.319 0.054 group
Model (b) 0.209 <0.001 0.195 <0.001 0.464 BMI
Model (c) 0.256 <0.001 0.047 0.043 -0.219 HDL-cholesterol
Model (a) 0.069 0.027 0.069 0.027 0.205 group
Model (b) 0.288 <0.001 0.219 <0.001 0.471 BMI
Stepwise method was used to analyze predictors. Exception was the group, where the method was enter.
β-value (coefficient)
Single predictor is an addition to the previous model.
NOTE: Explained change (∆T0 - T1 / ∆T0 - T2) was not included in the model.
Threat experience (∆T0-T1): Model (a): group (Ɛ4+, Ɛ4- and control group); model (b): group and systolic blood pressure (T0-T2);
model (c): group, systolic blood pressure (T0-T2) and total cholesterol (T0-T2)
Dietary fat quality (∆T0-T1): Model (a): group; model (b): group and body fat percentage (T0-T2)
Triglycerides (∆T0-T2):  Model (a): group; model (b): group and  BMI (T0-T2); model (c): group, BMI (T0-T2) and HDL-cholesterol (T0-T2);
Waist circumference (∆T0-T2): Model (a): group; model (b): group and BMI (T0-T2)
Threat experience 
(∆T0-T1)
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6 DISSCUSSION 
6.1 Using APOE genotype-based health information to promote healthy life-
styles. 
In this dissertation study, both short-term (10 weeks after the baseline) and long-term (6 and 
12 months after the baseline) psychological, behavioral and clinical effects of hereditary ge-
netic information were examined. Changes in state anxiety, threat experience, stage of change, 
dietary fat quality, the consumption of vegetables, berries and fruits,  high-fat and high-sugar 
foods as well as alcohol consumption, exercise and health and taste attitudes were measured. 
Additionally, the effects on serum lipids, blood glucose, blood pressure, BMI, body fat per-
centage and waist circumference were analyzed.    
6.1.1 Prevalence of APOE genotype and clinical descriptive 
Approximately a quarter (26.2%) of the participants had an Ɛ4 allele (3/4, 4/4) placing them 
at an increased risk for CVD and the most common APOE genotype was APOE 3/3 (59.8 %). 
This result is nearly consistent with previous findings (Lehtimäki et al. 1990; Schiele et al. 
2000).  However, the prevalence of different APOE genotypes differs between continents and 
countries (Lehtimäki et al. 1990; Corbo and Scacchi 1999; Schiele et al. 2000). Among north-
ern Europeans, for example, 30 % are APOE ԑ4 carriers, whereas in South Europe there are 
correspondingly less i.e. 20 % (Schiele et al. 2000).  
The result of Study III indicated that body fat percentage was the only clinical marker 
which differed significantly at the baseline between the APOE 4 allele and the APOE 2 or 3 
alleles. The trend for a higher total-, LDL- and HDL-cholesterol, but a lower level in triglyc-
erides were found among APOE 4 carriers compared with the APOE 2 and 3 carriers. These 
results are in accordance with recent studies (Maxwell et al. 2013; Downer et al. 2014). In 
contrast to some earlier findings, however, no evidence of APOE genotype effects on other 
cardiovascular risk factors were detected (Rantala et al. 1997; Helkala et al. 2001; Saito et al. 
2004; Carvalho-Wells et al. 2010). In previous studies, high blood pressure has been in some 
cases associated with the presence of APOE 4 allele (Rantala et al. 1997), but also with the 
APOE 2 allele (Couderc et al. 1993; Helkala et al. 2001; Cho et al. 2009). In addition, Helkala 
et al. (2001) noticed that carriers of APOE 2 allele had higher fasting glucose and 2 h blood 
glucose than APOE 3 and 4 carriers (Helkala et al. 2001). 
6.1.2 Effects of intervention 
Receiving personal genetic information, in combination with a personal health message had 
slight but favorable effects on dietary and cardiovascular risk markers. Both short-term and 
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long-term effects were found. In addition, short-term and slight long-term psychological ef-
fects, especially in threat experience were observed. 
This study was planned so that the first six months were the active period with intensive 
health communication, while the later six months period was a non-intensive period with no 
active communication with the study participants. During this active period, participants at-
tended the lectures and had an option to have a personal discussion with the doctor and re-
ceived two health messages and during the silent period was no communication between the 
study participants and research team. The silent period was designed to simulate life with 
exposure only to general health information.  
The results of the study indicated that the effects tend to diminish during the silent pe-
riod, which has also been reported in several previous studies. Commonly, enthusiasm for life 
style changes decreases during interventions (Yoon et al. 2013), which was also seen in this 
present study, especially in the control and Ɛ4- groups. Recent studies have found that a higher 
intervention intensity (including frequent counseling sessions) and a longer intervention du-
ration are more effective in achieving a permanent lifestyle change than less intensive and 
shorter interventions (Maderuelo-Fernandez et al. 2014; Wallace et al. 2014). Long-term and 
intensive health education has also been noticed to have a clearly positive effect in Finland 
(e.g. the North Karelia Project and FIN-D2D) (Saaristo et al. 2009; Borodulin et al. 2014), 
though the effect of the North Karelia Project is somewhat controversial (Ebrahim and Smith 
2001).  The results of this dissertation study indicated that even a very strong motivator, such 
as knowledge of a personal genetic risk may not be powerful enough to stimulate permanent 
health behavior change in the long-term without intensive repetition. There are several possi-
ble explanations for this. First, a lifestyle change demands continuous work and usually re-
quires several changes at the same time. The second, a permanent lifestyle change occurs 
slowly and is gradually tailored to individualized goals (Koenigsberg et al. 2004) and third, a 
permanent lifestyle change may also need a change in attitude. In addition, people’s values 
may affect the adoption of new health behavior (Schwartz 2011). 
However, this dissertation has shown that it is also possible to achieve long-term 
changes (12 months), which was the case in the triglyceride values.  There are several possible 
explanations (e.g. variation in responses toward dietary fat quality among APOE genotypes 
or the optimistic bias effect), why the long-term changes were detected only in triglyceride 
values, but not in health behaviors (e.g. dietary fat quality). These reasons discussed in detail 
later in this dissertation study (Chapter Effects on health behavior and cardiovascular risk 
markers). 
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Psychological effects 
Psychological effects are one concern when studying the consequences of genetic feedback. 
Both results (either susceptibility to disease or not susceptibility) can be harmful. The inher-
ited risk of a disease can cause anxiety and stress, but on the other hand negative test result 
can provide an explanation of an unhealthy lifestyle, if there is no recognized genetic risk of 
the disease (Lerman et al. 1997; McBride et al. 2002; Ito et al. 2006; Marteau and Weinman 
2006; Lovegrove and Gitau 2008). There are only a limited number of studies which have 
concentrated on studying the psychological effects of genotyping in lifestyle-related diseases. 
These studies have found that genetic screening only causes short-term psychological effects 
(Aktan-Collan et al. 2001; Meiser et al. 2002; Ashton et al. 2002; Andrews et al. 2004; Meiser 
et al. 2004; Claes et al. 2005; Kinney et al. 2005; Eborall et al. 2007; Heshka et al. 2008; Park 
et al. 2008; Collins et al. 2011). 
Results, based on Study I are mainly in line with those of previous studies, indicating 
that the psychological effects of personal genetic risk information were short-term, although 
the levels of A-State and threat experiences in the high-risk group (Ɛ4+) remained at a slightly 
higher level than at the baseline. In the case of motivation to make a lifestyle change (stage 
of change), every group (Ɛ4+, Ɛ4- and control group) had similar progression (from stage 2 
to stage 3) during the intervention. These results indicate that receiving personal genetic in-
formation had no significant impact on motivation towards a lifestyle change. 
In this present study, the opportunity was offered to have a personal discussion with a 
medical doctor and an elective genetic counseling lecture held by the professor of nutri-
genomics. Although only a few people took these opportunities (Table 6), these sessions had 
some effect on the threat experience and stage of change at the end of intervention. The find-
ings of Study I, inferred that the lecture increased the experience of threat toward CVD and 
those attending the personal discussion with the doctor were the more motivated participants. 
The participants who attended the personal discussion with the doctor, were all at stage 4 
(action, have changed their lifestyle within the last 6 months), while the participants, who did 
not attended the discussion were on average at stage 3 (preparation, ready, “have planned 
lifestyle change within next month”). In addition, participants, who attended the lecture, ex-
perienced threat more than the participants, who did not attend the lecture. These results fur-
ther support the idea that consultation and education have a significant effect on the under-
standing of gene results and the experience of worry (Henneman et al. 2002).  
Based on Study I, a trend for momentary anxiety existed shortly after receiving the in-
dividualized information about having a high-risk gene, APOE 3/4 or 4/4. This effect de-
creased over the subsequent months, but remained at a still higher level when compared to 
the baseline.  Receiving individualized information about having the low-risk gene, APOE 
2/3 or 3/3 had minor impact on the experience of A-State as it was quite stable in the Ɛ4- 
group during the whole intervention period. However, the control group responded contrary 
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to expectations, as they experienced an A-State in a very similar way to those in the Ɛ4+ 
group. There are few possible explanations for this outcome.  There is always the possibility 
of an external factor, which may confound the results. Stress, for example, can increase the 
A-state and on the contrary, relaxation can decreases it (Spielberger C 1971).  Second, there 
are differences in how people interpret and understand their results (Henneman et al. 2002). 
It is possible that the control group felt distressed because they were not provided with their 
genetic information at the beginning of the intervention. For instance, the delay in receiving 
the gene information may have caused concern and uncertainty.   
The results of Study I indicated that personal genotype-based health information and 
also knowing their potential risk for CVD (especially the high-risk gene, APOE 3/4 or 4/4) 
clearly affects, and more specifically increases, a person’s experience of the threat regarding 
CVD. This effect was the most intense directly after the genetic feedback. Some effects, how-
ever, also remained after 12 months. The results of Study IV also imply that the changes in 
cardiovascular threat experience may affected the actual changes in the participants own car-
diovascular risk markers (total cholesterol and systolic blood pressure), which further had an 
effect on changes in triglyceride values. The results imply that when the threat experience in-
creased, the triglyceride values decreased and our message, based on EPPM model was working 
correctly. The threat experience produced behavior change, which may affected the triglyc-
eride levels.   It may be possible that this outcome may be due to the nature of the CVD threat, 
which was strong enough to cause a sensation of danger for the Ɛ4+ group but not for the Ɛ4- 
group, who did not feel vulnerable to the threat of CVD. After genetic feedback (T0) partici-
pants in the Ɛ4- group could have felt relief, because they did not have a genetic susceptibility 
to CVD. According to Witte et al. (2001) lifestyle changes are best implemented when the 
threat is perceived as a danger, but not yet as a fear - and lifestyle change most often only 
happens when a person feels susceptible to threat, and the threat is personally large, but also 
when they have enough self-efficacy to observe the proposed action (Witte 1992; Witte 2001). 
Based on the results of Study I, none of the groups experienced fear, which means that our 
health message succeeded in creating danger, but not fear and therefore a lifestyle change is 
possible. 
The stage of change was used to measure readiness and motivation for changes in life-
style. Findings related to people’s motivation for lifestyle change have been contradictory in 
previous studies (Marteau et al. 2010; McBride et al. 2010). Very few studies have focused 
on using the stage of change instrument to measure lifestyle change in the context of using 
genetic testing to promote a healthy lifestyles. Stage of change is commonly used to investi-
gate smoking cessation; for example, a person’s stage of readiness for smoking cessation was 
found to be a significant predictor of them attempting to do so (DiClemente et al. 1991; 
Audrain et al. 1997; Campbell et al. 2013). The results of Study I infer that genetic feedback 
(especially in this study genotypes APOE 3/4 or APOE 4/4) had no effect on a person’s stage 
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of change with a similar progression (stage 2, contemplation to stage 3, preparation) in every 
group. There are several possible explanations for this: First, the genetic information may not 
be a good motivator for change, because people think that heredity is more powerful than 
their own behavior, and it could even have a negative impact on health behavior (Marteau & 
Weinman 2006) and second the fact that the APOE genotype is only one factor that can cause 
CVD, and not the only risk factor, could also affect people’s perceptions of it (Song et al. 
2004). In addition, the questionnaire concerning the stage of change is a very broad concept, 
as it asks “Have you considered lifestyle change?” It can be difficult to answer such a broad 
question, instead of asking “Have you changed your diet?” or even more precisely, “Have 
you increased your vegetables consumption?” 
Effects on health behavior and cardiovascular risk markers 
As stated in the literature view, cardiovascular disease is the sum of several non-modifiable 
(genetic, age, gender) and modifiable (obesity, dyslipidemia, high blood pressure, smoking, 
diabetes) risk factors, of which it is necessary to take note. Some health behavior changes 
may be easier to implement (e.g. changing dietary fat quality) than others (e.g. increasing 
vegetables consumption), depending, for example, on a very simple reason - that of seasonal 
variation in vegetable availability.  In addition, it has shown that changing existing habits is 
usually more difficult than adopting new habits (Fitzgibbon et al. 2007). Partly due to these 
challenges, there are a limited number of studies, although they are increasing, which have 
focused on purely to promote healthy lifestyles (e.g. diet, physical activity, cholesterol) by 
genotype based health information (McBride et al. 2010). Marteau et al. (2010), for example, 
concluded that genetic feedback did not affect smoking or exercise habits, but it can have 
some favorable effects on diet and lifestyle (Marteau et al. 2010b). However, results based on 
Studies II and III in this dissertation, indicated that receiving personal genotype based health 
information can have a slight, favorable, short-term effect, but also some long-term (12 
months) effects on diet and cardiovascular risk markers. The most significant effects of ge-
netic feedback were observed in the dietary fat quality, triglyceride values and waist circum-
ference, where the responses were greater in the Ɛ4+ group than in the Ɛ4- and control groups.  
The genotype-based health information for the Ɛ4+ group highlighted the importance of 
genotype in the response to dietary changes (e.g., improvement of fat quality) and in increased 
exercise. In addition, the health information emphasis the role of dietary changes for lowering 
cholesterol levels and a possibly lowered CVD risk. The purpose was to give an encouraging 
message, based on the facts that personal lifestyle choices together the genetics can have an 
impact on individuals’ health and risk factors. The content of the messages was based on the 
EPPM model and several previous studies reporting that carriers of the APOE ԑ4 allele are 
the most responsive to changes in dietary fat and cholesterol (Witte 2001; Masson et al. 2003; 
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Minihane et al. 2007). The results of Study II showed that the genotype-based health infor-
mation had an effect on dietary fat quality, but not exercise or the consumption of vegetables, 
berries and fruits, which could be one reason why in Study III; HDL, LDL and total choles-
terol level also stayed equal during the intervention. There is evidence that especially increas-
ing exercise has favorable effects on HDL cholesterol, and a high fiber diet (e.g. vegetables, 
berries and fruits and whole grain cereals) on the total and LDL-cholesterol (Wood et al. 1983; 
Anderson 1985; Brown et al. 1999). Other possible explanations could be the seasonal varia-
tion in vegetable, berries, and fruit consumption and a low-carbohydrate diet and the use of 
butter, which was a popular topic in the media of Finland during the intervention. 
Results of Study III indicated that the genotype-based health information had an impact 
on triglyceride values and waist circumference, but not cholesterol levels or other CVD risk 
markers. It is widely known that waist circumference differs between sexes, being higher in 
men. The difference in waist circumference was between Ɛ4+ group and control group and it 
was mainly caused by men. However, in contrast to expectations, the change in dietary fat 
quality did not explain the change in triglyceride values in Study IV. One possible explanation 
may be that the response toward dietary fat quality change indeed is different among APOE 
genotypes, which supports our EPPM based message and the previous studies (Masson et al. 
2003; Minihane et al. 2007). It can be possible that change in dietary fat quality affected 
change in triglyceride values in Ɛ4+ group, but not in Ɛ4- group, but due to the small group 
sizes it was not possible to perform a separate regression analysis for different groups. The 
other explanation could be that there were several, slightly favorable changes in health be-
havior and that those together affected triglyceride values in the long-term, but alone were 
not to a statistically detectable degree. In addition, because the health behavior questionnaires 
are self-reported, there is possibility of an optimistic bias–effect, which means that in the 
interview people are less likely to relate negative events, and are more likely to talk about 
positive events) (Miles and Scaife 2003).).  
When discussing genetic-dietary-interactions and nutrigenomics, there is no one right 
answer. Although there is evidence that the APOE 4 carriers are more responsive to the 
changes in dietary fat than other APOE carriers (Masson et al. 2003; Carvalho-Wells et al. 
2012), several controversial or non-associations have been presented (Minihane et al. 2000; 
Olano-Martin et al. 2010; Egert et al. 2010; Liang et al. 2013). Liang et al. (2013), for example 
did not find a different response towards fish oil fatty acids eicosapentaenoic (EPA) among 
the APOE genotypes. The only significant response was seen in HDL-cholesterol among 
APOE 2 carriers (Liang et al. 2013). Further, Minihane et al. (2000) showed in their studies 
that APOE ԑ4 carriers’ total cholesterol and LDL cholesterol increased after a fish oil supple-
mentation, and HDL cholesterol decreased compared with APOE ԑ3 carriers. (Minihane et al. 
2000). Egert et al. (2010) found that APOE ԑ3 carriers had a better response to quercetin 
(flavonols) supplementation than APOE ԑ4 carriers (Egert et al. 2010). These differences were 
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revealed in systolic blood pressure, HDL cholesterol, and ratio of LDL:HDL cholesterol 
(Egert et al. 2010). In this dissertation, Studies II and III found several, slight but favorable 
lifestyle changes (e.g. changes in fruit, berry, and vegetable consumption, in the consumption 
of high-fat and high-sugar foods, in health and taste attitudes and blood glucose (2h)), which 
were parallel in every intervention group. In these cases, a favorable lifestyle change may be 
explained by the Hawthorne effect (Noland 1959; McCarney et al. 2007), which means that 
progression and lifestyle changes are due rather to participating in the intervention and being 
examined than any impact of personal genetic risk information and thus making lifestyle 
changes accordingly. The other possible explanation can be the progression of a national 
awareness in nutrition (Helldán et al. 2013). In addition, Finns diet compliance, attitudes, and 
values toward general health education is fairly high attested to, for example, by the North 
Karelia Project, which managed to decrease CHD mortality rate by 80 % in people of working 
age during 1972 – 2007 (Borodulin et al. 2014). Based on Schwartz’s (2011), Cultural Value 
Orientations Classification, Finns are more committed and dutiful compared, for example, to 
people in the USA or Japan, which are characterized as being audacious and detached 
(Schwartz 2011). It may be possible that compared to Americans or the Japanese, Finns easily 
accept even very generic education, as was the case in the control group in this present study 
(Schwartz 2011). 
To best of author’s knowledge, this is the first explanatory study using APOE genotyp-
ing to affect health behavior with the aim of lowering the risk of cardiovascular disease, which 
also included the effects on clinical factors (Marteau et al. 2010). The assessments of the 
actual cardiovascular risk markers are important to include, because people may need to see 
their progression in concrete terms. People, for example, may realize that exercise is one im-
portant factor in the prevention of lifestyle-related disease,  but they do not understand the 
association between physical activity and actual metabolic risk factors (Vähäsarja et al. 2012). 
A previous study by Vähäsarja et al. (2012), conducted among people with a high risk of type 
2 diabetes (n = 7128), found that the individual’s overestimation of physical activity can be 
an obstacle to behavioral change (Vähäsarja et al. 2012). Increasing understanding about the 
connection between health behavior and metabolic risk factors and the inclusion of actual 
cardiovascular risk markers, may achieve better results. Lowered cholesterol levels, for ex-
ample, may motivate people to extend further the changes in their health behavior. However, 
the effects may also be the opposite, if the desired change does not occur (Marteau and 
Weinman 2006), and then people can become depressed and regress back to under the base-
line level. Clinical outcomes may also act as a ‘control’ for the self-reporting behaviour 
changes (e.g. diet).  
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6.1.3 Potential interactions and associations between the changes in different lifestyle 
factors 
Study IV was planned to analyze associations between different lifestyle changes and it was 
not able to demonstrate connections between lifestyle behaviors (dietary fat quality, consump-
tion of vegetables, berries, and fruits, consumption of high fat and sugary foods, consumption 
of alcohol and physical activity) and actual cardiovascular risk markers (e.g. triglyceride val-
ues and waist circumference). These results were the opposite of previous studies, which have 
shown that unhealthy lifestyle behaviors (e.g. physical inactivity, smoking, excessive con-
sumption of alcohol and saturated fat and low consumption of vegetables) are closely linked 
to an increased risk of cardiovascular diseases (Raitakari et al. 1995; O’Neil et al. 1997; Ma 
et al. 2000; Schuit et al. 2002; Lukasiewicz et al. 2005; Matikainen 2009). The result was 
somewhat contrary to the expectations and there can be several possible explanations, which 
have been discussed in a previous chapter (Effects on health behavior and cardiovascular risk 
markers). 
In addition, Study IV showed that changes in psychological factors (threat experience, 
state anxiety, stage of change) did not directly explain the changes in clinical markers (e.g. 
triglyceride values and waist circumference), although threat experience may have had effect 
on triglyceride values through total- and HDL cholesterol (Fig. 12).  
Furthermore, Study IV did not find any connection between attitude changes and behav-
ioural change. In addition, Study II showed that genetic feedback did not affect health and 
taste attitudes and change in dietary fat quality was short-term. These results of Study II and 
IV imply that behavioural changes (e.g. dietary fat quality) can occur without attitude 
changes, but that long-term and permanent change may also demand change in attitudes. Alt-
hough there are several studies which have presented the fact that health attitudes are closely 
linked to health behaviour (Kearney et al. 1998; Zandstra et al. 2001; Roininen et al. 2001; 
Hearty et al. 2007; Talvia et al. 2011), controversial studies have also been presented (Lloyd 
et al. 1993). The study by Lloyd et. al (1993) found that participants, who consumed high-fat 
diets had similar attitudes to dietary change (to a low-fat and more healthy diet) compared 
with those consuming low-fat diets (Lloyd et al. 1993). The link between attitudes and health 
behaviour is not so unambiguous and according to Glasman et al. (2006) attitudes affect future 
behaviors, if they are easy to recall, stable over time, and decisive instead of ambivalent 
(Glasman and Albarracín 2006). In our study, the focus was the change in attitudes, therefore 
if the participants perhaps expressed ambivalent attitudes, this could be the one reason why 
the link between attitudes and health behaviour changes did not occur.  
In this dissertation study, several health indicators were used to measure a change. Study 
IV showed that BMI was the strongest predictor for changes in the values of triglycerides and 
waist circumference, which indicates that, if the BMI has decreased the triglyceride values 
and waist circumference also decreased. In addition, other clinical markers, such as body fat 
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percentage, total- and HDL cholesterol had interaction-effects on the triglyceride values and 
waist circumference. These results are in line with those of previous studies, which have found 
that risk factors for cardiovascular diseases tend to accumulate (Raitakari et al. 1995; Schuit 
et al. 2002; Pronk et al. 2004; Lukasiewicz et al. 2005; Poortinga 2007; Artaud et al. 2013; 
Robinson et al. 2013).          
6.1.4 Limitations 
Study population and background variables 
The group sizes were relatively small, which was partly due to limited resources and strict 
qualification for participants. The selection criteria for participants were strict and only 
healthy individuals were included in the study. In this study, men were in the minority and 
somewhat older than the women. Any long-term medication or disease was an exclusion cri-
terion. In addition, many of the CVD risk markers (e.g., waist circumference, fat percent, and 
HDL cholesterol) are known to differ between sexes, but due to the small group sizes, statis-
tical analyses between men and women were impossible to conduct.  This dissertation study 
found statistical significant difference in the change of waist circumference between Ɛ4+ and 
the control group and it was produced by the men. However, the percentage of men was al-
most equal in those groups. Changes in body fat percentage and HDL cholesterol did not 
differ between the groups or sexes during the intervention. However, despite the small group 
sizes and the very healthy individuals included, we managed to achieve some significant dif-
ferences between the different groups. It is reasonable to first carry out this kind of very sen-
sitive, explanatory research among healthy people. It may be possible that lifestyle change 
with healthy people signals further clearer changes among less healthy people. 
The randomization was done to divide the participants into the intervention and control 
groups before genotyping, and therefore the group sizes differed. This difference was purely 
due to the number of carries with APOE 3/4 and 4/4. At the baseline, 34.4% of the participants 
in the intervention group were APOE 4 carries, which is consistent with previous findings 
(Lehtimäki et al. 1990; Schiele et al. 2000).         
Underreporting and also an optimistic bias –effect occurs when people self-report their 
diet (Mattisson et al. 2005; Yannakoulia et al. 2006). Women tend to underreport more than 
men (Mattisson et al. 2005; Yannakoulia et al. 2006). This may have had some effects on 
results, as women were in the majority among the participants. However, to control for an 
optimistic bias –effect, we also performed clinical assessments in our study. 
It is also impossible to control all the external factors, although some external factors 
(e.g. education, marital status, family history of cardiovascular, or Alzheimer’s disease) could 
have been considered in this dissertation. Previous studies have shown, for example, that low 
socioeconomic status predicts mental disorders (e.g. depression or anxiety) (McLeod and 
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Shanahan 1993; Rutter 2003). We had several psychological and behavioral questionnaires, 
so we asked only a few background questions (sex, age, A-trait) to avoid peoples’ frustration 
in having to answer to many questionnaires. 
Assessments and procedure 
The motivation toward lifestyle change (stage of change) was only measured by one question 
based on the validated Transtheoretical Model and some non-validated dietary and physical 
activity questionnaires were used in the study.  However, these questionnaires are widely used 
in Finland.  The motivation toward lifestyle change –questionnaire, used in Study I, is the 
only validated questionnaire in Finnish, so it was justified to choose this questionnaire which 
is well known. Validated dietary and physical activity questionnaires, used in Study II are not 
available in Finnish, and international questionnaires would have had to be tailored in order 
to apply them to Finnish dietary and physical activity habits.  
We had four different measuring times (T0, T1, T2 and T3) during the one year inter-
vention. Health behavioral and attitude questionnaires were completed at each measuring 
time, but the psychological questionnaires were completed at the baseline (T0), two weeks 
after the genetic feedback (T1) and at the end of the intervention (T3). The clinical assess-
ments were at the baseline (T0), after six months (T2) and the end of the intervention (T3). 
This variation in measuring times (T0, T1, T2 and T3) produces some challenge to analyzing 
the predictors in Study IV. However, it was reasonable to ask about the psychological factors 
immediately after the genetic feedback and in contrast the effect on the clinical markers may 
be reflected after several months. In addition, we did not want to burden participants by asking 
them to attend and answer several questionnaires and assessments at the same time. 
Only one genotype (APOE) was analyzed in this dissertation study. This choice was 
relevant when the study was designed (in 2010). The APOE was then amongst the most widely 
studied genotypes in gene-diet interactions, and carriers of the APOE 4 allele are more com-
mon in Finland than, for example, in southern Europe (Lehtimäki et al. 1990; Schiele et al. 
2000). However, nowadays the costs of genotyping have decreased and several variants in the 
genes of lipid metabolism are known to interact with dietary fat intake and dietary fatty acid 
composition, thus affecting the risk of metabolic diseases (Phillips 2013; Wetterstrand 2014). 
In addition, there are many gene variants that remain unknown as of yet (Phillips 2013). In 
this dissertation, the genotype-based health information was based on the evidence that APOE 
carriers have higher total and LDL cholesterol than carriers of other alleles (Masson et al. 
2003; Minihane et al. 2007). However, there are studies that have found controversial results 
or no connection at all among different APOE genotypes and dietary fat (Minihane et al. 2000; 
Egert et al. 2010).  
Some other factors, which could have caused bias in our study and results, are low-
carbohydrate diets and the use of butter, which was a popular topic in the Finnish media, and 
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occurred simultaneously with the intervention. In addition, communicated increased AD risk 
of APOE 4 carriers, which was one criterion for ethical permission and very limited number 
of participants in voluntary lecture and personal discussion could have caused some bias in 
our study. 
6.1.5 Further research suggestions and practical implications 
In light of the limitations, and due the very explanatory nature of this dissertation study, fur-
ther research will be required. There is a need for individual, genotype-based health and die-
tary advice, in order for genotyping in prevention of lifestyle-related diseases might increase 
in the future. This is why more research is needed utilizing genetic screening aimed at pre-
venting lifestyle-related diseases. Genetic screening may be a potential tool in public health 
care for the early diagnosis and prevention of disease. Lifestyle diseases are multifactorial, 
and there are several genes that may predispose individuals to disease risk, for example, dia-
betes mellitus, high blood pressure, CVD, etc. in combination with the environment. This 
information can be used to develop tailored interventions, including health information based 
on genotyping that would aim at preventing lifestyle diseases. There are several factors which 
can affect an individual’s background (e.g. socioeconomic status, attitudes toward genetic 
testing), therefore further studied that are more focused on the factors which affect the adop-
tion and utilization of genetic information, are suggested.  
Based on Study I, genetic testing does not have a strong effect of people’s anxiety and 
the threat experience in the long-term. The study supports the fact that the effect of APOE 
genotype-based health information on psychological factors may not be an obstacle for using 
genotyping to promote healthy lifestyles (dietary, exercise) in healthy adults. According to 
Aatre and Day (2011), the genetic feedback may raise some apprehension in people of the 
potential impact of their lifestyle choices and at the same time give them hope and strengthen 
their will and commitment (Aatre and Day 2011).  This study used the EPPM model to create 
a health risk messages in the context of the genotype-based health information promoting 
healthy lifestyles. However, as stated in literature review, this model is a fairly new and 
unique approach to promote healthy lifestyles in combination with the ‘real’ threat i.e. the 
inherited genotype and the ‘perceived’ threat. Consequently, more research is needed about 
how to utilize the EPPM model in the context of genotype-based health promotion studies.  
Nevertheless, to achieve better results, every targeted, health behavior promotion intervention 
should include some kind of health behavior model (Glanz et al. 2008). One future research 
aspect in lifestyle-related diseases field could be focused on creating targeted health risk mes-
sages, which could be based on the psychological properties of individuals, e.g. motivation, 
threat experience or self-efficacy. Further, comparing different kinds of models to promote 
healthy lifestyles (e.g. models based on health risk messages and genotype information and 
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models based on enhancing motivation (e.g. motivational interviewing)) could be an im-
portant aspect of future research. 
A permanent health behavior change may depend on attitudes, and other psychological 
factors so further studies, including several psychological factors (e.g. motivation, stress 
level, depression, self-efficacy, attitudes, values and health-related meanings) are recom-
mended. Permanent lifestyle changes occur individually and gradually, therefore future stud-
ies on the current topic should include a longer follow-up time, intensive repetition, and tar-
geting. In addition, people usually tend to adopt one or only a few, lifestyle change at a time, 
so future research should put more focus on implementing only one or two precisely defined 
lifestyle changes.  
To best of the author’s knowledge, this is the first study using APOE genotype-based 
health information to affect health behavior, which also takes into account clinical risk mark-
ers and psychological factors. In Study IV it was shown that attitude, psychological- and be-
havioral changes did not directly explain the changes in cardiovascular risk markers (e.g. tri-
glycerides, waist circumference), although change in threat experience may have affected 
changes in triglyceride-values through total- and HDL cholesterol.  This may indicate some 
optimistic bias –effect, which is important to take note of when planning further research. 
Actual clinical markers can act as a ‘control’ for self-reporting behavioral questionnaires. In 
addition, one possibility could be that response in triglyceride values may indeed vary be-
tween APOE genotypes due to the various changes in dietary fat quality. This is also one 
valuable aspect for consideration in future studies. 
Currently, the challenge is the direct-to-consumer genetic tests (DTC), which can be 
purchased from the Internet without any control. DTC tests do not offer any opportunity for 
genetic counseling and the given nutritional advice is very generic without any emotional 
support.  One research aspect could combine these DTC genetic tests and an opportunity for 
a consultation with a doctor. Despite the fact that the cost of genotyping has decreased, genetic 
screening in the prevention of lifestyle-related diseases is not routine practice in public health 
care (Bloss et al. 2011; Voils et al. 2012). There is a lack of know-how among health care 
professionals and a lack of resources (Mountcastle-Shah and Holtzman 2000; Taloustutkimus 
Oy and The Finnish Innovation Fund 2013). In the future, more effort should be put into 
educating nutritionists and doctors in the field of genotyping for the prevention of lifestyle 
related diseases. It could be economically worthwhile to research which has the more benefi-
cial affect: (1) individual, genotype-based health information combined with only a few meet-
ings with a nutritionist and doctor or (2) very general dietary advice, combined with several 
meetings with healthcare professionals. 
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7 CONCLUSIONS  
This dissertation study has given some indications that individualized APOE genotype-based 
health information may be one potential practical tool to be used in the future by clinical 
professionals in public health care for preventing lifestyle-related diseases. However, more 
research as well all more expertise among health care professionals is needed.  
 
The results of the study indicate that: 
 
1. Genetic information, based on the APOE genotype causes short-term and only slightly 
long-term anxiety and threat. Psychological factors may not be an obstacle for using 
CVD-related APOE genotyping to promote healthy lifestyles in healthy adults. 
2. APOE-genotype based dietary and physical activity advice has positive effects on die-
tary and CVD-risk markers. Positive short-term effects were found in dietary fat quality 
and waist circumferences. A positive long-term (12 months) effect was found in triglyc-
eride values. 
3. The positive effect tended to diminish after the active communication period. Even in 
the case of very personal health information, to achieve permanent health behavior 
change, attitudes are important, as well as intensive repetition and a longer intervention 
duration. 
4. Changes in psychological factors (anxiety- and threat experience, motivation), health 
and taste attitudes, and health behavioral factors (dietary, alcohol consumption, physical 
activity) did not directly explain the changes in triglyceride values and waist circumfer-
ence. However, changes in cardiovascular threat experience may have affected changes 
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TIEDOTETTAVIA ASIOITA TUTKIMUKSEN J ATKOSTA 
 
Noin viikon kuluessa teille lähetetään sähköpostitse täytettä-
viä kyselyitä, jotka ovat myös tärkeä osa tutkimusta. Tämän 
takia toivomme niihin pikaista vastausta. Heihin, joilla sähkö-
postia ei ole käytössä, otetaan yhteyttä puhelimitse. 
Ka i k i l l e  v a p a a e h t o i n e n  p e r i n n ö l l i s y y s n e u v o n t a  – t i l a i s u u s  
j ä r j e s t e t ä ä n  9 . 1 2 . 2 0 1 0  k l o  1 7  –  1 9 ,  Se i n ä j o e n  k e s k u s s a i r a a -
l a n  (Hanneksenrinne 7) a u d i t o r i o s s a  ( = pääovesta sisään ja 
aulasta raput yksi kerros ylöspäin (raput ovat neuvontaa vas-
tapäätä)). Ravitsemuksesta ja APO E:n vaikutuksesta koleste-
roliin luennoi kliininen ravitsemustieteilijä, maa- ja elintarvi-
ketalouden tutkimuskeskuksen (MTT) professori Raija Tahvo-
nen. Paikalla on myös Etelä-Pohjanmaan sairaanhoitopiirin 
johtajaylilääkäri, Hannu Puolijoki, jonka kanssa on mahdolli-
suus henkilökohtaiseen 5 – 10 minuutin keskusteluun geeni-
perimän (APO E) vaikutuksesta elämäntapoihin ja sairastumis-
riskiin. Tilaisuudessa on tarjolla pieni iltapala. 
Ta r j o i l u n  v u o k s i  p e r i n n ö l l i s y y s n e u v o n t a  – t a p a h t u m a a n  o n  i l -
m o i t t a u d u t t a v a  v i i m e i s t ä ä n  1 . 1 2 . 2 0 1 0  j o k o  s ä h k ö p o s t i t s e  
hlhieta@utu.fi t a i  p u h e l i m i t s e  0 4 0 -4 4 4 4 0 8 4 .  Il m o i t t a u t u m i s e n  
y h t e y d e s s ä  o n  m y ö s  m a i n i t t a v a ,  m i k ä l i  h a l u a t t e  v a r a t a  a j a n  
h e n k i l ö k o h t a i s e e n  k e s k u s t e l u u n  a s i a n t u n t i j a n  k a n s s a .  
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